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ABSTRACT	OF	THESIS	
	
DESIGN,	SYNTHESIS,	AND	ANTICANCER	ACTIVITY	OF	RUTHENIUM	COMPLEXES	
Ruthenium	complexes	show	promise	as	light	activated	photodynamic	therapy	(PDT)	
prodrugs.	Strained	octahedral	complexes	were	synthesized	that	produce	a	cytotoxic	
species	upon	light	activation.	pUC19	DNA	damage	in	vitro	experiments	were	carried	
out	to	determine	the	type	of	damage	observed.	In	vivo	cell	experiments	were	carried	
out	on	the	non‐small	 lung	cancer	A549	cell	 line	to	determine	the	phototherapeutic	
window	 of	 the	 synthesized	 complexes.	 One	 mechanism	 of	 drug	 resistance	 via	
elevated	levels	of	glutathione	was	addressed	through	in	vitro	binding	studies	carried	
out	with	UV‐Vis	spectroscopy	and	in	vivo	glutathione	titrations	in	the	A549	cell	line.	
Several	 complexes	 were	 shown	 to	 be	 potential	 PDT	 agents	 with	 light‐activated	
activities	greater	than	cisplatin	and	10‐100	fold	lower	dark	toxicities.	
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Chapter	1:	Introduction	
In	 2008,	 12.7	 million	 new	 patients	 were	 diagnosed	 with	 cancer	 and	 7.6	
million	patients	died	from	cancer	related	issues.1	The	disease	does	not	discriminate	
between	 societies,	 afflicting	 economically	 developed	 and	 developing	 countries	
alike.1	 The	 term	 cancer	 applies	 to	 a	 broad	 swath	 of	 diseases	 characterized	 by	 the	
inability	 of	 an	 abnormal	 cell	 to	 regulate	 growth,	 allowing	 it	 to	 potentially	 form	
tumors.	 Disruption	 of	 the	 regulation	 of	 normal	 tumor	 suppression	 genes	 and	
activation	 of	 oncogenes	 lead	 to	 this	 abnormal	 growth	 and	 fast	 track	 the	
development	 of	 the	 disease.	 The	 combination	 of	 over	 expression	 of	 cell	 growth	
promoters	and	increased	cellular	survival	mechanisms	allow	the	abnormal	cells	to	
proliferate.2		
Common	cancer	therapies	include	surgery,	radiotherapy,	and	chemotherapy.3	
Combinations	 of	 the	 three	 are	 common	 based	 on	 the	 location	 of	 the	 cancer,	 risk	
factors,	 and	 potential	 for	 successful	 outcomes.4	 Chemotherapy	 involves	 the	 use	 of	
antineoplastic	drugs	to	kill	cells	that	divide	rapidly.	Current	drugs	in	the	clinic	can	
be	divided	into	categories	based	on	their	mechanism	of	action	to	prevent	replication	
of	 rogue	cells,	 and	many	cause	DNA	damage	 leading	 to	apoptosis.	Drug	categories	
include	 alkylating	 agents,	 antimetabolites,	 anthracyclines,	 plant	 alkaloids,	 and	
topoisomerase	inhibitors.5,6,7,8,9		
Approximately	50%	of	people	undergoing	chemotherapy	are	treated	with	the	
alkylating	agent,	cisplatin.10	Cisplatin	 is	used	to	treat	a	variety	of	cancers	 including	
testicular,	ovarian,	head,	and	neck	cancers.11	The	drug	works	by	covalently	binding	
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to	 DNA,	 rendering	 the	 cell	 unable	 to	 undergo	 cellular	 division.	When	 DNA	 repair	
mechanisms	 fail	 to	 work,	 apoptosis	 results.12	 Cisplatin	 and	 similar	 platinum	
complexes	 favor	 the	 N7	 position	 of	 pyrimidines	 and	 the	 N3	 position	 of	 purines	
(Figure	1.1).13		
Figure	1.1:	Base	pairs	shown	numbered	and	hydrogen	bonded	
Guanine	(G)	–	Cytosine	(C)	
Adenine	(A)	–	Thymine	(T)	
	 	 	
	 Cisplatin	is	capable	of	platinating	double	stranded	DNA	through	intrastrand	
and	interstrand	mechanisms.14	The	majority	of	cytotoxic	interactions	arise	from	the	
intrastrand	cross‐linking	of	adjacent	purines.	Guanosine	is	preferred	over	adenosine,	
and	 cisplatin	 favors	 intrastrand	 binding	 of	 adjacent	 guanosines,	 but	 will	 also	
coordinate	 adenosines	 adjacent	 to	 guanosine.	 Interstrand	 complexes	 are	 lesser	
realized	 and	 provide	 similar	 damage.15	 All	 of	 these	 structures	 distort	 the	 DNA	
structure	and	activate	cellular	DNA	damage	mechanisms	such	as	the	expression	of	
p53,	and	apoptosis.16		
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Drug	 resistance	 for	 platinum	 compound	 chemotherapy	 is	 thought	 to	 arise	
from	 many	 mechanisms,	 including	 detoxification	 by	 cellular	 sulfur‐containing	
compounds.17	 Glutathione	 is	 a	natural	 tripeptide	 found	 in	 the	 cytosol	 of	 almost	 all	
cells	in	concentrations	up	to	16	mM.18,19,20	The	sulfur	rich	compound	is	a	good	ligand	
for	 platinum	 according	 to	 Pearson’s	 hard	 soft	 acid	 base	 theory.21	 Other	 sulfur	
containing	metal	detoxification	agents	such	as	metallothionein	have	been	 found	 in	
similar	 concentrations	 in	 cisplatin‐insensitive	 cells.	 These	 detoxifying	 agents	
interfere	 with	 the	 chemotherapeutic	 role	 of	 platinum	 compounds	 and	 are	 a	
substantial	 contributor	 to	 increased	 drug	 resistance.22	 	 Several	 derivatives	 of	
cisplatin	such	as	oxaliplatin	and	carboplatin	have	been	synthesized	with	the	goal	to	
thwart	resistance,	decrease	toxicity	and	improve	activity.23	Figure	1.2	shows	several	
structures	 of	 platinum	 compounds	 that	 are	 currently	 in	 clinical	 trials	 and	
commercially	 available	 for	 therapeutic	 use.24,25	 These	 platinum	 derivatives	 work	
through	 the	 same	DNA	damage	mechanism	 and	 share	dose	 limiting	 toxicities	 and	
adverse	 side	 effects	 observed	 with	 cisplatin.26	 These	 side	 effects	 include	
nephrotoxicity,	nausea,	ototoxicity,	and	electrolyte	disturbance.27		
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Figure	1.2:	Current	platinum	chemotherapeutic	agents	
Trade	Name	 Complex	Structure	
carboplatin	
oxaliplatin	
	
AMD473	
JM216	(satraplatin)	
	
	 Despite	 the	 toxicity	 and	 side	 effects	 of	 cisplatin	 and	 other	 platinum	
derivatives,	these	drugs	(in	combination	with	other	therapeutics)	are	quit	successful	
in	 treating	a	variety	of	cancers.28,29,30	Building	on	this	success,	other	metal	centered	
drugs	have	been	synthesized	 in	an	attempt	to	minimize	adverse	effects.31,32	Several	
metals	 including	 ruthenium,	 rhenium,	 and	 osmium	 have	 been	 investigated	 as	
possible	chemotherapeutics.33	Ruthenium	compounds	are	a	potential	alternative	to	
their	 platinum	 counterparts	 due	 to	 the	 decreased	 toxicity	 and	 variable	 oxidation	
states	 accessible	 under	 physiological	 conditions.34	 Two	 ruthenium	 drugs,	 NAMI‐A	
and	KP1019	are	currently	in	clinical	trials	(Figure	1.3).35,36		
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Figure	1.3:	Ruthenium	drugs	currently	in	clinical	trials	
Trade	Name	 Complex	Structure	
NAMI‐A	
KP1019	
	
	
NAMI‐A	is	an	arene	Ru(III)	drug	that	is	used	for	treatment	of	non‐small	cell	
lung	 cancer	 through	 reducing	 metastases	 weight	 without	 affecting	 the	 primary	
tumor.	 It	 is	well	 tolerated	 by	 patients	 in	 clinical	 studies.37	 KP1019	 is	 activated	 by	
reduction	 from	 RuIII	 to	 RuII	 in	 hypoxic	 tumor	 tissues	 by	 reducing	 sulfur	 rich	
biomolecules	 such	 as	 glutathione.34	 KP1019	 has	 been	 used	 in	 clinical	 trials	 for	
colorectal	cancer	and	is	also	well	tolerated	in	patients.	36		
Ruthenium	 polypyridyl	 complexes	 have	 also	 been	 investigated	 for	 their	
potential	 chemotherapeutic	 qualities.	 These	 complexes	 are	 well	 studied,	 and	
derivatives	of	 the	ruthenium	polypyridyl	complex	have	been	synthesized	to	 target	
DNA.34,38	Due	to	the	rich	synthetic	nature	of	ruthenium,	several	complexes	containing	
ligands	 with	 high	 DNA	 affinity	 have	 been	 synthesized.	 The	 groove	 binding	 and	
6	
	
metallo‐intercalating	 ability	 of	 1,10	 phenanthroline	 (phen)	 and	 dipyrido	 [3,2‐f:	 2’,	
3’‐h‐quinoxaline]	(dpq)	(see	Table	2.1)	are	well	known.39		
NAMI‐A	and	KP1019	provide	of	novel	chemotherapeutics	outside	of	cisplatin	
and	 display	 how	 transition	 metals	 can	 provide	 several	 interesting	 complex	
structures	 capable	 of	 leading	 to	 apoptosis.	 Alternatively,	 the	 DNA	 binding	
ruthenium	compounds	 in	 the	 literature	provides	 an	 alternative	 to	platinum	drugs	
with	 a	 non‐covalent	 mechanism	 of	 DNA	 interactions.	 The	 problem	with	 all	 these	
approaches,	 however,	 is	 the	 lack	of	 specificity,	 as	 these	drugs	do	not	discriminate	
between	healthy	and	cancerous	cells.		
To	 improve	 selectivity	 and	 decrease	 toxicity,	 photoactive	 complexes	 can	
increase	the	therapeutic	window	of	antitumor	drugs.		For	this	reason	photodynamic	
therapy	 (PDT)	 can	 be	 used	 to	 treat	 localized	 tumors	 with	 laser‐based	 fiber‐optic	
devices.40	 	 PDT	 is	 used	 to	 treat	 a	 variety	 of	 cancers	 accessible	with	 a	 light	 source	
including	 lung,	 superficial	 gastric,	 cervical,	 bladder,	 head,	 and	 neck.	 	 Patients	
utilizing	PDT	benefit	from	the	relatively	non‐invasiveness	of	the	treatment	that	can	
often	be	 administered	 in	 an	 outpatient	 setting.41	 	 This	 targeted	 treatment	 reduces	
the	side	effects	associated	with	traditional	chemotherapy	and	because	dose‐limiting	
toxicity	 is	 nonexistent,	 toxicity	 is	 only	 induced	 in	 the	 targeted	 tissues	when	 light	
activated.	Repeated	treatments	are	therefore	possible.		Photofrin	is	clinically	used	to	
treat	 early	 and	 advanced	 stage	 lung	 cancer	 and	 Foscan	 is	 used	 in	 treatment	 of	
palliative	head	and	neck	cancer	(see	Figure	1.4).42,43		
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Figure	1.4:	Photosensitizers	available	for	chemotherapeutic	use	
Trade	Name	 Complex	Structure	
Photofrin	
Foscan	
Levulan	
Metvix	
	
	
Topical	 photosensitizers	 such	 as	 Levulan	 and	 Metvix	 are	 biosynthetic	
precursors	 to	 photofrin,	 and	 are	 used	 in	 the	 clinic	 to	 treat	 actinic	 keratosis.44	 The	
benefit	of	 these	drugs	 lies	 in	 the	mechanism	of	action.	These	catalytic	 compounds	
form	 singlet	 oxygen	 as	 they	 absorb	 the	 light	 energy,	 becoming	 excited	 and	
transferring	the	energy	to	triplet	excited	oxygen	(3O2).	This	energy	transfer	causes	
one	of	the	unpaired	valence	electrons	to	flip,	fueling	the	production	of	the	cytotoxic	
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singlet	 oxygen	 (1O2).45	 Added	 selectivity	 arises	 from	 the	 inability	 of	 the	 highly	
reactive,	 short‐lived	 species	 to	 diffuse	 across	 more	 than	 one	 membrane,	 causing	
minimal	damage	to	normal	tissue.46	The	drawback	to	the	singlet	oxygen	mechanism	
arises	from	the	apoxic	nature	of	malignant	and	more	aggressive	cancer	cells.	
Photoactivatable	metal	complexes	have	been	investigated	as	alternative	PDT	
therapeutics	 to	 porphyrin	 based	 photosensitizers.	 Photoactive	 octahedral	 PtIV	
complexes	 have	 been	 investigated	 due	 to	 their	 ability	 when	 light	 activated	 to	 be	
reduced	 to	 their	 cytotoxic	 PtII	 species.	 These	 complexes	 show	 better	 aqueous	
solubility	and	increased	therapeutic	indexes	with	reduced	toxicity.33	One	drawback,	
however,	 is	 the	 need	 to	 activate	 the	 PtIV	 species	 with	 high	 energy	 UV	 light.	
Polypyridyl	 ruthenium	complexes	have	also	been	 investigated	due	 to	 the	 fact	 that	
various	 structures	 can	 be	 readily	 synthesized	 and	 possess	 tunable	 absorption	
properties.47	 Long	 wavelength	 light	 is	 desired	 in	 PDT	 due	 to	 its	 increased	 tissue	
penetration.	Low	energy	transitions	that	absorb	at	longer	wavelengths	in	the	MLCT	
(metal‐to‐ligand‐charge	transfer)	region	are	an	important	attribute	in	the	design	of	
the	 metal‐based	 compounds.	 Various	 groups	 have	 developed	 several	 metal	
complexes	 that	 display	 light	 induced	 cytotoxicity	 through	 oxygen	 independent	
mechanisms.48,49		
Due	to	the	rich	nature	of	the	synthetic	chemistry	associated	with	ruthenium	
compounds,	 and	 the	 promising	 clinical	 results	 of	 NAMI‐1,	 KP1019	 and	
photoactivatable	platinum	complexes,	alternative	light‐active	ruthenium	complexes	
hold	promise	as	potential	anti‐cancer	agents.		The	goal	of	this	research	project	is	to	
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produce	novel	ruthenium	compounds	that	display	low	to	no	activity	in	the	dark	in	
both	in	vivo	and	in	vitro	experiments,	but	can	be	turned	on	by	light	to	become	potent	
cytotoxic	 agents.	We	 aim	 to	make	 efficient	 light	 activated	 complexes	 that	 display	
high	DNA	binding,	crosslinking,	or	other	forms	of	DNA	damage,	resulting	in	toxicity	
in	cancer	cells.		The	primary	factor	considered	for	light‐activated	agents	is	the	ratio	
of	 the	 activity	 in	 light	vs.	 in	 the	dark,	which	 is	 termed	 the	phototherapeutic	 ratio.	
This	 is	 a	 direct	 measurement	 of	 the	 therapeutic	 window	 for	 PDT.	 	 Several	
compounds	have	been	synthesized,	 characterized,	and	screened	 in	cancer	cells	 for	
beneficial	anti‐tumor	behavior	 in	 this	work.	 	The	goals	defined	at	 the	onset	of	 the	
project	 included	 light‐activated	 potencies	 comparable	 to	 cisplatin,	 and	 a	 10‐fold	
phototherapeutic	 ratio,	 allowing	 for	 the	 potential	 of	 significant	 reduction	 in	 side‐
effects	in	future	clinical	applications.	The	progress	towards	achieving	these	goals	is	
described	 in	 the	 following	 chapters.	 The	 thesis	 is	 divided	 into	 the	 following	
chapters:	 Design,	 synthesis,	 in	vitro	 and	 in	vivo	 characterization	 of	 the	 complexes	
synthesized	 for	 this	 thesis.	 Several	 scientists	 contributed	 to	 this	 work	 and	 are	
appropriately	cited	for	the	work	they	contributed.		
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Chapter 2: Design and Synthesis 
 
1: Design 
	
The	 photochemistry	 of	 ruthenium	 polypyridyl	 complexes	 such	 as	
[Ru(bpy)3]2+	 have	 been	 extensively	 studied.1	 The	 unique	 combination	 of	 chemical	
stability,	 redox	 properties,	 excited‐state	 reactivity,	 luminescence	 emission,	 and	
excited‐state	lifetime	of	[Ru(bpy)3]2+	and	its	derivatives	has	garnered	the	attention	
of	 researchers	 across	 multiple	 disciplines.2Ru(II)	 polypyridyl	 complexes	 play	 key	
roles	in	multiple	research	areas	such	as	photophysics,	photocatalysis,	and	electron	
and	 energy	 transfer.1The	 photochemical	 and	 photophysical	 nature	 of	 these	
compounds	is	of	interest	to	our	group	and	will	be	the	main	focus	of	this	chapter.	The	
hypothesis	of	this	project	is	that	light‐activated	Ru(II)	complexes	can	be	designed	to	
eject	 ligands	 upon	 irradiation,	 producing	 ligand	 deficient	 systems	 that	 will	 react	
with	 and	 crosslink	DNA,	 like	 cisplatin.	 The	 application	 of	 these	 systems	 is	 for	 the	
development	 of	 photo‐responsive	 chemotherapeutic	 agents.	 The	 key	 feature	 that	
controls	 this	photochemical	 reaction	 is	 intramolecular	 strain,	 generating	distorted	
Ru(II)	 complexes	 that	 undergo	 photochemical	 reactions	 with	 low	 energy,	 visible	
light.	
Unstrained	 Ru(II)	 polypyridine	 complexes	 such	 as	 [Ru(bpy)3]2+	 contain	
ligands	with		donor	orbitals	that	are	localized	on	the	nitrogen	atoms	and		donor	
and	 *	 acceptor	 orbitals	 delocalized	 on	 the	 aromatic	 rings.	 Ru(II)	 polypyridyl	
complexes	are	 typically	orange	 to	 red,	due	 to	 their	absorption	of	visible	 light.	The	
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absorption	 spectrum	 of	 [Ru(bpy)3]2+	 is	 shown	 in	 Figure	 2.1awith	 the	 electronic	
transitions	assigned.		
Figure	 2.1:	 Electronic	 absorption	 spectrum	 of	 a)	 [Ru(bpy)3]2+	 and	 b)	 GL002	
[Ru(bpy)2‐6,6’‐dmbpy]2+in	dH2O.	
	
	 The	intense	band	at	285nm	results	from	spin‐allowed,	ligand	centered	(LC)		
to	*	transitions.		The	intense	metal‐to‐ligand	charge	transfer	(MLCT)	bands	at	240	
and	450nm	result	 from	spin	allowed	d	 to	*	 transitions.	The	 less	 intense	shoulder	
bands	at	320	and	340nm	result	from	metal‐centered	(MC),	M	to	Mtransitions.			
Figure	2.2a	shows	a	simplifiedJablonski	diagramfor	excitation	of	an	electron	
by	 following	absorption	of	 a	photon	with	promotion	 from	 the	ground	 state	 to	 the	
1MLCT.	
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Figure	 2.2:	 Electronic	 transitions	 of	 (a)	 unstrained	 d6	 Ru(II)	 complexes	 and	 (b)	
strained	d6	Ru(II)	complexes.	
(a)	
	
(b)	
	
	
Once	the	1MLCT	excited	state	is	populated,	 intersystem	crossing	efficiently	funnels	
electrons	 to	 the	 lower	 3MLCT	excited	state.1Radiative	relaxationfrom	the	 3MLCT	to	
the	ground	state	of	[Ru(bpy)3]2+	produces	an	intense	emission	band	at	610nm	and	is	
shown	in	Figure	2.3a.	
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Figure	2.3:	Emission	profile	of	a)	[Ru(bpy)3]2+	and	b)	[Ru(bpy)2dmbpy]2+.	
Long	luminescent	lifetimes	of	800	ns	are	reported	for	the	transition	from	the	
3MLCT	excited	state	to	ground	state	with	a	quantum	efficiency	of	~0.06.1Population	
of	 the	 3MC	state	 for	 [Ru(bpy)3]2+is	 inefficient,	producing	a	poor	quantum	yield	 for	
photodecomposition	on	 the	order	of	10‐5‐10‐2.1For	unstrained	d6	Ru(II)	 complexes	
such	 as	 [Ru(bpy)3]2+,	 population	 of	 the	 3MC	 state	 is	 inefficient	 due	 to	 the	 large	
energy	 gap	 between	 the	 3MLCT	 and	 3MC,	 resulting	 mainly	 in	 emission	 from	 the	
3MLCT	state.		
Absorption	profiles	similar	to	[Ru(bpy)3]2+	are	observed	in	strained	d6	Ru(II)	
polypyridine	complexes.		The	emission	profile	of	the	complex	Ru(bpy)2‐6,6’‐dmbpy,	
GL002,	is	shown	in	Figure	2.3b.	In	contrast	to	standard	octahedral	Ru(II)	complexes,	
strained	complexes	undergo	fast	radiationless	deactivation	to	the	ground	state.	This	
occurs	 through	 ligand	 dissociation	 reactions	 when	 the	 3MC	 state	 is	 lowered	 in	
energy	 so	 that	 it	 can	 be	 accessed	 thermally	 from	 the	 3MLCT	 state.	 Synthesis	 of	
sterically	 strained	 ruthenium	 complexes	 decreases	 the	 3MLCT	 to	 3MC	 energy	 gap,	
allowing	population	of	the	3MC	excited	state,	resulting	in	cleavage	of	the	Ru‐N	bond.	
Figure	 2.2b	 shows	 this	 in	 analtered	 Jablonski	 diagram,	 and	 depicts	 how	 electrons	
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are	successfully	shuttled	to	the	3MC	excited	state	orbitals.	The	efficient	population	of	
the	3MC	state	is	manifest	in	the	decreased	intensity	of	the	emission	spectra	shown	in	
Figure	2.3b.	
Upon	photo‐excitation	of	the	complex,	a	bond	is	broken	to	a	bipyrine	ligand,	
and	 a	 monodentate	 bipyridine	 intermediate	 with	 a	 ruthenium	 that	 is	
pentacoordinated	forms.	In	the	presence	of	excess	electron	donating	ligands	such	as	
chloride	 ions	or	 solvent	molecules,	 new	bonds	 to	 the	 ruthenium	can	 form.	At	 this	
point,	are‐coordination	process	can	occur,	reforming	the	Ru‐N	bond	or	alternatively,	
the	single	remaining	bond	to	the	bipyridine	ligand	can	be	broken,	forming	a	Ru(II)	
complex	with	 two	 chloride	 or	 two	 solvent	 ligands.	 The	 re‐coordination	process	 is	
possible	 with	 unstrained	 octahedral	 complexes	 such	 as	 [Ru(bpy)3]2+,while	 ligand	
loss	prevails	 in	 the	model	 compound	GL002,	due	 to	 the	 steric	 clash	of	 the	methyl	
groups.		
Photolabile	 model	 complexes	 with	 the	 Ru(bpy)2	 backbone	 containing	
sterically	crowding	ligands	such	as	6,6’‐dimethyl‐2,2’‐bipyridinehave	been	prepared	
to	 promote	 the	 population	 of	 the	 3MC	 excited	 state,	 leading	 to	 the	 complete	
dissociation	of	the	 ligand.	This	generates	the	 ligand	deficient,	bis‐bipyridine	Ru(II)	
complexcapable	of	cross‐linking	DNA.	Several	photo‐active	complexes	utilizing	 the	
Ru(bpy)2	backbone	have	been	synthesized	including	GL002,	003,	006,	007,	008,	010,	
and	014	 (see	Table	2.2).	The	rate	at	which	 the	complexes	photo‐dissociate	can	be	
tuned	 through	 the	 choice	 of	 ligands.	 The	 complex	 GL002	 has	 fast	 photoejection	
kinetics	 (t1/2=1.9	minutes,	 see	 Table	 3.1)	 due	 to	 the	 free	 rotation	 about	 the	 2,2’‐
15	
	
carbon‐carbon	 bond	 of	 6,6’‐dimethyl‐2,2’‐bipyridine.	 In	 contrast,	 addition	 of	 rigid	
ligands	to	the	Ru(bpy)2backbone	slows	the	ejection	process.	For	example,	when	the	
2,9’‐dimethyl‐1,10‐phenanthroline	 ligand	 is	 incorporated(see	 GL007,	 Figure	 2.5),	
at1/2	 of	 112.8minutes	 is	 obtained,	 as	 shown	 in	 Table	 3.1.	 This	 is	 attributed	 to	 the	
ligands’	ability	to	re‐coordinate	the	metal,	due	to	its	rigid	chelating	structure.		
The	DNA	affinity	of	the	complexes	can	also	be	tuned	through	the	addition	of	
intercalating	 ligands	 such	 as	 dpq	 (dipyrido[3,2‐f:2’,3’‐h‐quinoxaline])	 and	 dppz	
(dipyrid0[3,2‐2',3'‐c]phenazine)	(see	Table	2.1).	These	planar	ligands	are	known	to	
intercalate	 into	 the	base	 stack	of	DNA.3	 Complexes	GL003,	 009,	 010,	 021	 and	039	
were	synthesized	to	test	if	photoejecting	complexes	with	DNA	intercalating	ligands	
are	more	 potent	 than	 compounds	with	 lower	DNA	 affinity.	 Unstrained	 complexes	
GL009	and	021	contain	dpq	and	dppz	ligands	that	display	bindingto	pUC19	DNAin	
vitro,	 as	 discussed	 in	Chapter	4.	 The	photoejectable	 analogues	of	 these	 complexes	
GL003,	 010,	 and	 039	were	 synthesized	 to	 explore	 their	 biological	 activity	 in	vitro	
and	in	vivo.		
Complexes	with	different	overall	charge	states	and	alterative	backbones	have	
been	 prepared	 to	 determine	 how	 these	 factors	 change	 the	 invitro	 and	 invivo	
experimental	results.	Ruthenium	compounds	with	different	overall	charges	such	as	
GL005	(overall	charge	of	‐2)	and	008	(overall	charge	of	0)	display	different	cytotoxic	
properties.	Decreased	affinity	to	the	negatively	charged	DNA	backbone	is	thought	to	
account	for	some	of	the	differences	in	biological	activities.Complexes	with	different	
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Ru(dmphen)2	backbones	have	also	synthesized.	GL018,	019,	022,	023,	and	039	are	
examples	of	these	complexes	(see	Table	2.2).		
Complexes	GL018	and	019	contain	hydroxyquinoline	ligands	that	are	known	
to	 be	 cytotoxic.4These	 complexes	 were	 designed	 to	 test	 the	 hypothesis	 that	
complexes	 could	 be	 generated	 that	 would	 create	 two	 active	 species	 –	 the	 ligand	
deficient	 Ru(II)	 complex,	 and	 the	 liberated	 ligand.	 Studies	 have	 shown	 that	
hydroxyquinoline	and	its	derivatives	have	anti‐proliferative	and	cytotoxic	effects	in	
leukemia	 cells	 lines.5	 They	 inhibit	 RNA	 synthesis	 in	 E.	 coli	 bacteria	 and	 iron	
complexes	 containing	 these	 ligands	 have	 been	 shown	 to	 be	 effective	 in	 the	U937,	
K562,	ML2,	 and	HL60	cell	 lines.6	 In	addition,	hydroxyquinoline	derivatives	 chelate	
copper,	and	acts	as	angiogenesis and proteasome inhibitors in prostate cancer cell lines.7	
An	 effort	 has	 been	 made	 to	 produce	 ruthenium	 complexes	 that	 absorb	 at	
longer	wavelengths,	as	longer	wavelength	(lower	energy)	light	can	penetrate	deeper	
into	 tissues.	 Thiswould	 provide	 access	 to	 tumors	 previously	 unreachable	 via	
photodynamic	 therapy.	 Addition	 of	 the	 biquinoline	 (biq)	 ligand	 to	 the	 Ru(phen)2	
backbone	 (see	 Table	 2.2)	 produces	 a	 60	 nm	 red	 shift	 in	 the	 UV/Vis	 profile	 of	
complex	 GL011	 (see	 Figure	 3.2).	 Alternatively,	 cyclometallating	 ligands	 2‐
phenylpyridine	 and	 7,8‐benzoquinoline	 coupled	 with	 the	 Ru(bpy)2	 backbone	
produced	complexes	GL034	and	035	(see	Table	2.2).These	cyclometallated	systems	
display	 	 100	 nm	 red	 shifts	 in	 their	 corresponding	 UV‐Vis	 profiles	 (Figure	 3.1).	
Unfortunately	these	compounds	do	not	eject	as	they	are	unstrained,	and	are	unable	
to	populate	the	3MC	excited	state.	In	the	future,	strained	and	photo‐active	analogues	
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of	 these	 systems	 should	 be	 synthesized	 to	 determine	 their	 in	 vitro	 and	 in	 vivo	
properties.	 Finally, oxygen containing hydroxyquinoline ligands also act to lower the 
energy of the MLCT excited state, potentially red-shifting the absorption of the 
complexes further into the PDT therapeutic window. Derivatives of complexes 
containing the backbones presented in this work with different quinolines should be 
synthesized to evaluate their phototherapeutic ratio. 	
2. Synthesis 
	
Several	scientists	contributed	to	the	synthesis	chapter,	including	Dr.	Edith	Glazer,	
Erin	Wachter,	and	Emily	Hall.	
	 Several	ruthenium	complexes	were	synthesized	to	gain	an	understanding	of	
how	the	structural	characteristics	affect	the	photophysics	and	photochemistry	of	the	
complexes	 and	 theirin	 vitroactivities	 with	 pUC19	 DNA	 (Chapter	 4)	 and	 in	
vivopotencies	 in	 the	 A549	 cell	 line	 (Chapter	 5).	 	 Complexes	 that	 produce	 an	
activated	 species	 upon	 exposure	 to	 light	were	 prepared	 to	 observe	 differences	 in	
light	and	dark	activity	with	DNA.		
The	general	preparation	of	these	complexes	begins	with	the	synthesis	ofthe	
ligands	used	 (Figure	2.4)	 and	 then	generating	 the	Ru(L)2Cl2	 starting	material	 (see	
Figure	 2.5).	 	 The	 synthetic	 nature	 of	 ruthenium	 (see	 Chapter	 1)	 allows	 efficient	
combinatorial	design.	Mono	ligands	ejected	from	synthesized	complexes	upon	light	
activation	that	show	toxicity	can	be	incorporated	into	the	bis‐Ru	backbone	resulting	
in	 massive	 libraries	 that	 can	 be	 screened	 against	 the	 cell	 line.	 Several	 ligands	
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utilized	in	this	thesis	were	synthesized	to	test	how	structural	planarity	of	the	ligand	
effect	 the	photoejection	kinetics,	 in	vitro,	 and	 in	vivo	 results.	The	general	 synthetic	
pathway	to	produce	the	ligand(s)	is	shown	in	Figure	2.4.	These	are	good	reactions,	
with	yields	of	60%	or	greater.8,9	
Figure	2.4:	General	synthesis	of	extended	polyaromatic	ligands	
	Once	 the	 appropriate	 ligands	 are	 synthesized,	 the	 desired	 ruthenium	 complex	
starting	material	can	be	produced	with	the	reaction	scheme	shown	in	Figure	2.5	in	
good	yields.10	
Figure	2.5:	Synthesis	of	the	ruthenium	starting	material	with	two	bidentate	ligands	
	
With	 the	 synthesized	 starting	materials,	modular,	 high	 yielding	 complexes	 can	 be	
produced.11	The	reactions	and	subsequent	purification	are	carried	out	in	diminished	
light	conditions	to	prevent	photo‐degradation	of	the	complexes.	
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Figure	2.6:	Addition	of	a	third	ligand	to	produce	efficient	phototherapeutic	agents	
	General	preparation	of	complexes	with	Ru(L)2Cl2	backbone:	
	 A	 solution	 of	 RuCl3	 (3.8	 mmol,	 1	 g),	 free	 ligand	 L	 (7.6mmol,	 variable	 g)	
LiCl(57	mmol,	2.4	g)	and	ascorbic	acid	(4.2	mmol,	0.74	g)	were	added	to	25	mL	dry	
DMF	and	refluxed	at	150oC	for	12	hours.	The	solution	was	allowed	to	cool	to	room	
temperature,	 and	 the	 purple	 product	 was	 precipitated	 with	 a	 mixture	 of	 cold	
acetone/ether	(50	mL	each).	The	precipitate	was	collected	by	vacuum	filtration	and	
washed	with	acetone/ether	and	dried	under	vacuum.	The	yield	of	Ru(phen)2Cl2	 is	
65%	and	Ru(dmphen)2Cl2	is	71%.	
General	preparation	of	complexes	with	Ru(L)2L’‐2PF6:		
A	 solution	of	 0.38mmol	Ru(L)2Cl2	(0.1	 g)	 and	0.42	mmol	L’(variable	 g)	was	
added	to	4	mL	ethylene	glycol	in	a	pressure	tube	and	heated	at	150	oC	for	~4	hours.	
The	 solution	 was	 allowed	 to	 cool	 and	 poured	 into	 50	 mL	 of	 dH2O.	 	 A	 saturated	
solution	 of	 aq.	KPF6	 was	 added	 to	 precipitate	 the	 complex	 as	 the	 PF6	 salt.	 The	
precipitate	was	collected	by	vacuum	filtration	and	washed	with	water	(50	mL)	and	
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ether	 (50	 mL)	 and	 dried	 under	 vacuum.	 A	 non‐emissive,	 dim	 spot	 on	 thin	 layer	
chromatography	(TLC)	(0.1%	saturated	KNO3/20%H2O/80%MeCN	on	silica	plates)	
is	evidence	that	the	strained	complex	has	formed	(see	Figure	2.2b).		
For	unstrained	complexes,	the	starting	materials	were	added	to	50:50	water:	
ethanol	and	refluxed	at	100	 oC	 for	4	hours.	The	solution	was	poured	 into	~50	mL	
dH2O	 and	 the	 excess	 ligand	was	 extracted	with	methylene	 chloride.	 Saturated	aq.	
KPF6	was	added	and	the	PF6	salt	was	extracted	in	methylene	chloride.	The	layer	was	
dried	over	magnesium	sulfate,	filtered	and	concentrated	under	reduced	pressure.	A	
bright,	 emissive	 spot	 observed	 using	 TLC	 conditions	 described	 above	 is	 evidence	
that	the	unstrained	complex	has	formed	(see	Figure	2.2a).	Similar	purification	of	the	
complexes	 was	 carried	 out	 using	 flash	 chromatography.	 Complexes	 were	 loaded	
onto	 the	 column	 in	 acetonitrile	 and	 eluted	 with	 a	 ramping	 gradient	 of	 0.1%	
saturated	KNO3/20%H2O/80%MeCN.	The	synthesized	complexes	 typically	elute	at	
9%	dH2O.	Solvent	was	removed	under	reduced	pressure	and	reconstituted	in	25	mL	
of	 dH2O.	 A	 saturated	 aq.	 solution	 of	 KPF6	was	 added,	 and	 the	metal	 complex	was	
extracted	into	methylene	chloride.	Removal	of	the	solvent	under	reduced	pressure	
gave	pure	PF6	complex	salts.		
General	procedure	to	counter‐ion	exchange	to	produce	water‐soluble	complex	salts:	
Saturated	 tetra‐n‐butyl	 ammonium	chloride	 (1	 g	 in	5	mL	dry	 acetone)	was	
added	 to	 the	 PF6 complex salts dissolved in minimal acetone. The resulting 
precipitate was filtered in a long stem hersch funnel packed with glass wool. The 
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precipitate was washed with acetone and eluted with acetonitrile. The solvent 
was removed under reduced pressure to yield the water soluble Ru(L)2L’-2Cl salt. 	
Synthesis	of	1,10‐phenanthroline‐5,6‐dione	(phendione):12	
	 4	g	(20	mmol)	1,10‐phenanthroline	and	3.6	g	(30	mmol)	KBr	was	added	to	a	
125	mL	round	bottom	flask	and	chilled	in	an	ice	bath.	1.5:1	mixture	of	concentrated	
H2SO4:	 HNO3(40/20	mL	 respectively)	 were	 added	 dropwise	 to	 the	 flask.	 Caution:	
The	 reaction	 is	 very	 exothermic	 and	 evolves	 bromine	 gas.	 The	 reaction	 should	 be	
carried	out	in	the	hood	with	the	hood	sash	at	a	minimum	height.	Care	should	be	taken	
handling	the	concentrated	acids.	Following	addition	of	the	acid	mixture,	the	solution	
was	refluxed	for	3	hours	at	100	oC.	The	solution	was	removed	from	heat	and	allowed	
to	cool	to	room	temperature.	The	bright	orange	solution	was	poured	over	500	mL	of	
ice	 in	a	 large	beaker	and	the	 flask	was	rinsed	with	 ice	and	was	slowly	neutralized	
with	NaOH	pellets	producing	a	milky,	dark	yellow	solution.	Care	should	be	taken	to	
not	overshoot	the	neutral	pH	producing	a	basic	solution.	At	basic	pH’s,	the	solution	
turns	green	and	result	in	decreased	yields.		The	product	was	extracted	in	CHCL3	and	
dried	 over	 magnesium	 sulfate	 producing	 a	 clear	 yellow	 solution	 that	 was	
concentrated	 using	 rotary	 evaporation	 and	 dried	 under	 vacuum.	 The	 methylated	
analogue	 2,9‐dimethyl‐1,10‐phenanthroline‐5,6‐dione	 (dmphendione)	 was	
prepared	in	a	similar	method	using	the	2,9‐dimethyl‐1,10‐phenanthroline	(dmphen)	
starting	material.		
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Synthesis	of	dipyrido[3,2‐f:2’,3’‐h‐quinoxaline	(dpq):13	
	 Caution:	 Phendione	 is	 a	 flocculent	 solid	 and	 is	 a	mucous	 irritant.	To	 reduce	
exposure,	tare	the	reaction	flask	and	transfer	the	material	in	the	fume	hood.	1	g	(47.5	
mmol)	phendione	and	350	mL	ethanol	were	added	to	a	500	mL	round	bottom	flask.	
0.49	 mL	 (d=0.899	 gcm‐3,71	 mmol)1,2‐diaminoethane	 was	 added	 to	 the	 flask	
(solution	 golden	 brown)	 and	 heated	 at	 40	 oC	 for	 2	 hours.	 The	 reaction	 was	
monitored	 by	 TLC	 using	 10%	methanol	 in	 methylene	 chloride.	 The	 reaction	 was	
removed	from	heat	and	allowed	to	stir	for	5	hours	at	room	temperature	producing	a	
golden,	brown	solution.		The	solution	was	reduced	by	rotary	evaporation	to	yield	a	
white	solid	that	was	recrystallized	from	boiling	methanol	to	yield	an	off‐white	solid.	
The	 dimethyl	 analogue	 of	 this	 ligand	was	 prepared	 in	 a	 similar	method	 using	 the	
dmphendione	starting	material	with	similar	yields.		
Synthesis	of	dipyrid0[3,2‐~:2',3'‐c]phenazine	(dppz):13‐14	
	 1	 g	 (47.5	 mmol)	 phendione	 and	 0.77	 g	 (71	 mmol)	 1,2‐phenylene‐diamine	
were	added	 to	 a	120mL	pressure	 tube	with	1:2	EtOH:	dH2O	 (30	mL:	60	mL).	The	
pressure	tube	was	placed	in	an	oil	bath	at	180oC	and	stirred	for	3	hours	producing	a	
brownish‐orange	 solution.	 Caution:	A	blast	 shield	 should	be	utilized	with	 the	hood	
sash	at	minimum	height	to	reduce	explosion	hazards.	The	reaction	tube	was	removed	
from	heat	and	allowed	to	cool	producing	a	feathery,	yellow	solid	that	was	collected	
by	vacuum	filtration.	Additional	crops	of	precipitate	were	obtained	upon	cooling	the	
mother	liquor	and	were	collected	by	vacuum	filtration.		Similar	TLC	conditions	used	
in	the	synthesis	of	the	dpq	ligand	were	used	to	monitor	the	reaction.	The	dimethyl	
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analogue	 (dmdppz)	 of	 this	 ligand	 was	 prepared	 in	 a	 similar	 method	 using	 the	
dmphendione	starting	material	with	similar	yields.		
Spectroscopic	Characterization	of	Synthesized	Ligands:		
1,10‐phenanthroline‐5,6‐dione	(phendione):	
Yield:	3.8	g	(90%).1H	NMR	(CDCL3,	400	MHz):	1H	NMR	(CDCl3):δ	9.05	(d,	J=4.76	Hz,	
2H),	8.43	(d,	J=7.51	Hz,	2H),	7.53	(t,	J=6.23,	2H).	
2,9‐dimethyl‐1,10‐phenanthroline‐5,6‐dione	(dmphendione):	
Yield:	1.9	g	(75%).	1H	NMR	(CDCL3,	400	MHz):	1H	NMR	(CDCl3):δ	8.36	(d,	J=8.06	Hz,	
2H),	7.40	(d,	J=7.76	Hz,	2H),	2.83	(s,	3H).		
Dipyrido[3,2‐f:2’,3’‐h‐quinoxaline	(dpq):	
Yield:	1.03	g	(92.8%).1H	NMR	(CDCL3,	400	MHz):	 1H	NMR	(CDCl3):δ9.47	(d,	 J=8.24	
Hz,	2H),	9.27	(d,	J=4.40	Hz,	2H),	8.97	(s,	2H),	7.78	(td,	6.22	Hz,	4.40	Hz,	2H).	
Dimethyl‐dipyrido[3,2‐f:2’,3’‐h‐quinoxaline	(dmdpq):	
Yield:	1.1	g	(88%).	1H	NMR	(CDCL3,	400	MHz):	1H	NMR	(CDCl3):δ	9.37	(d,	J=8.24	Hz,	
2H),	8.93	(s,	2H),	7.65	(d,	J=8.42	Hz,	2H),	3.07	(s,	6H).			
Dipyrido[3,2‐f:2',3'‐c]phenazine	(dppz):	
Yield:	872	mg	(65%).	1H	NMR	(CDCL3,	400	MHz):	1H	NMR	(CDCl3):δ	9.17	(d,	J=8.15	
Hz,	2H),	8.90	(d,	J=4.49	Hz,	2H),	8.01	(d,	J=6.59	Hz,	2H),	7.78	(d,	6.50	Hz,	2H),	7.61	
(td,	J=6.23	Hz,	6.41	Hz,	2H).	ESI	MS	calcd	for	C18H10N4[M]+282.1,	found	283	[M]+.	
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Dimethyl‐dipyrid0[3,2‐~:2',3'‐c]phenazine	(dmdppz):	
Yield:	0.9	g	(65%).	1H	NMR	(CDCL3,	400	MHz):	1H	NMR	(CDCl3):9.50	(d,	J=8.24	Hz,	
2H),	8.31	(d,	J=6.59	Hz,	2H),	7.81	(d,	J=6.50	Hz,	2H),	7.63	(d,	J=8.24	Hz,	2H),	2.97	(s,	
6H).	).	ESI	MS	calcd	for	C20H14N4[M]+310.12,	found	311	[M]+.	
Spectroscopic	Characterization	of	Synthesized	Ruthenium	Complexes:	
Complexes	 GL005,	 GL008,	 and	 GL013	 are	 sulfonate	 or	 carboxylate	 containing	
complexes	that	could	not	be	 isolated	 from	water	due	to	solubility.	Because	of	 this,	
NMR	data	could	not	be	obtained.	ESI‐MS	data	are	given	for	each	complex.		
Ru(bpy)2dmbpy,	GL002:	
Yield:	297	mg	(87%).		1H	NMR	(CD3CN,	400	MHz):		8.48	(d,	J=8.24	Hz,	2H),	8.40	(d,	
J=8.42	Hz,	2H),	8.27	(d,	J=8.42	Hz,	2H),	8.08	(td,	J=8.06,	1.65	Hz,	2H),	7.96‐7.90	(m,	
6H),	7.62	(d,	 J=5.31	Hz,	2H),	7.46	(td,	 J=5.86,	1.65	Hz,	2H),	7.29	(d,	 J=6.59	Hz,	2H),	
7.21	 (td,	 J=7.32,	 1.47	 Hz,	 2H),	 2.14	 (s,	 6H).	 13C	 NMR	 (CD3CN):	 	 166.69,	 159.91,	
158.68,	 158.44,	 154.06,	 152.90,	 139.22,	 138.85,	 138.81,	 129.18,	 128.49,	 128.29,	
125.47,	125.39,	123.18,	25.62.	ESI	MS	calcd	 for	C32H28N6Ru	 [M]+	598.1,	 [M]2+	299;	
found	598.3	[M]+,	299.1	[M]2+.	Purity	by	HPLC:	98.8%	by	area.UV/Vis	(MeCN)	ε:	247	
nm	(23100),	289	(72500),	452	(13900).	
Ru(bpy)2dmdpq,	GL003:	
Yield:	284	mg	(77%).1H	NMR	(CD3CN,	400	MHz):	9.51	(d,	 J	=	8.4	Hz,	2H),	9.17	(s,	
2H),	8.5	(dd,	J	=	8.24,	8.24	Hz,	4H),	8.02	(quin,	J	=	7.69,	4H),	7.72‐7.80	(m,	6H),	7.29	
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(t,	 J	 =	6.68,	4H),	2.19	 (s,	6H).	 13C	NMR	(CD3CN):		 169.63,	158.65,	158.52,	154.14,	
152.98,	 151.44,	 147.69,	 139.84,	 139.05,	 138.84,	 134.96,	 129.47	 129.04,	 128.53,	
128.49,	125.62,	125.54,	26.51.	 	ESI	MS	calcd	for	C36H28N8Ru	[M]+	674.1,	[M]2+	337;	
found	673.1	[M]+,	336.9	[M]2+.	Purity	by	HPLC:	95.1%	by	area.UV/Vis	(MeCN)	ε:	256	
nm	(49700),	289	(65100),	452	(13100).	
Ru(bpy)2phen,	GL004:	
Prepared	per	literature	procedure.15	1H	NMR	(CD3CN,	400	MHz):	8.41	(d,	J=	8.02	Hz,	
2H),	8.36	(d,	J=8.2	Hz,	2H),	8.01	(s,	2H),	7.91	(t,	J=	7.8	Hz,	2H),	7.78	(dt,	J=10.7	Hz,	5.3	
Hz,	4H),	7.53	(t,	J=	6.60,	2H),	7.45	(d,	J=	5.0,	2H),	7.25	(t,	J=	6.3,	2H),	7.01	(t,	J=6.25,	
2H).	 13C	 NMR	 (CD3CN):	 157.23,	 157.02,	 151.96,	 151.65,	 151.61,	 147.49,	 137.47,	
137.36,	 136.55,	 130.75,	 127.81,	 126.97,	 126.93,	 126.93,	 126.80,	 125.46,	 123.88,	
123.82.	Additional	13C	peaks	due	to	concentration	dependent	molecular	aggregation	
through	 π‐stacking	 in	 solution.16ESI	 MS	 calcd	 for	 C32H24N6Ru	 [M]2+	 287.01,	 found	
287	[M]2+.	Purity	by	HPLC:	98.1%	by	area.	
Ru(bpds)2dmbpy,	GL005:	
ESI	MS	calcd	for	C60H40N6O12RuS4	[M]2‐633.03,	found	632.6	[M]2+.	
Ru(bpy)2‐3,3’‐dmbpy,	GL006	
Yield:	150	mg	(90%).			1H	NMR	(CD3CN,	400	MHz):	8.50	(d,	J=7.6	Hz,	4H),	8.05	(m,	
4H),	7.83	(d,	J=7.8	Hz,	4H),	7.70	(d,	J=5.6	Hz,	2H),	7.59	(d,	J=	5.1	Hz,	2H),	7.39	(m,	4H),	
7.26	 (s,	2H),	2.47	 (s,	6H).	 13C	NMR	(CD3CN):		 148.28,	158.159,	158.053,	153.081,	
150.606,	 141.89,	 138.71,	 138.67,	 137.87,	 128.50,	 128.34,	 126.80,	 125.28,	 125.19,	
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21.38.	ESI	MS	calcd	for	C32H28N6Ru	[M]2+	299.07,	found	299.1	[M]2+.	Purity	by	HPLC:	
98.8%	by	area.	UV/Vis	(MeCN)	ε:240	nm	(26500),	289	(71600),	453	(13500)	
Ru(bpy)2dmphen,	GL007	
Yield:	160	mg	(95%).	1H	NMR	(CD3CN,	400	MHz):	1H	NMR	(CD3CN):		8.57	(d,	J	=	8.0	
Hz,	2H),	8.50	(d,	J	=	7.8	Hz,	2H),	8.09	(dt,	J	=	8.0,	1.4	Hz,	2H),	8.05	(s,	2H),	8.02	(td,	J	=	
8.2,	1.5	Hz,	2H),	7.82	(d,	J	=	5.8	Hz,	2H),	7.77	(d,	J	=	5.8	Hz,	2H),	7.78‐5.59	(m,	4H),	
7.34	 (td,	 J	 =	 9.0,	 1.4	 Hz,	 2H),	 7.31	 (td,	 J	 =	 9.0,	 1.4	 Hz,	 2H),	 2.0	 (s,	 6H).	 13C	 NMR	
(CD3CN):		167.50,	158.75,	158.4,	1554.01,	153.96,	152.82,	152.86,	150.53,	150.34,	
138.90,	 138.74,	 136.87,	 130.79,	 130.62,	 130.14,	 128.94,	 1218.86,	 128.53,	 128.48,	
128.41,	 128.34,	 125.87,	 125.59,	 125.49,	 26.49.16ESI	 MS	 calcd	 for	 C34H28N6Ru	 [M]‐
+622.14,	 found	 [M]+621.2,	 [M]2+311.1.	 Purity	 by	 HPLC:	 99.9%	 by	 area.	 UV/Vis	
(MeCN)	ε:287	nm	(60200),	452	(12800).		
Ru(bpy)2bcds,	GL008:	
ESI	MS	 calcd	 for	 C46H34N6O6RuS2	[M]+	932.10,	 [M]2+466.1	 found	 [M]+	 955.3	 (+Na),	
[M]2+	488.9	(+Na).	
Ru(bpy)2dppz,	GL009:	
Yield:	133	mg	(35%).	1H	NMR	(CD3CN,	400	MHz):	1H	NMR	(CD3CN):		9.32	(dd,	J	=	
8.24,	1.5	Hz,	2H),	8.60	(t,	J	=	9.18	Hz,	4H),	8.20‐8.13	(m,	6H),	8.06	(t,	J	=	7.69	Hz,	2H),	
7.98‐7.91	(m,	4H),	7.84‐7.77	(m,	4H),	7.52	(t,	J	=	6.32	Hz,	2H),	7.36	(t,	J	=	6.87	Hz,	2H).	
13C	NMR	(CD3CN):		158.27,	158.07,	154.77,	153.20,	153.06,	151.56,	143.84,	141.12,	
139.06,	 138.97,	 134.58,	 133.62,	 1311.95,	 130.71,	 128.70,	 128.55,	 128.50,	 125.41,	
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125.35.	ESI	MS	calcd	for	C38H26N8Ru	[M]+696.13,	[M]2+	348.1	found	[M]+841.1	(PF6),	
[M]2+	348.0.	Purity	by	HPLC:	98.7%	by	area.	UV/Vis	(MeCN)	ε:	255	nm	(40600),	285	
(85000),	367	(16400),	448	(16000).		
Ru(bpy)2dmppz,	GL010:	
Yield:	133	mg	(35%).	1H	NMR	(CD3CN,	400	MHz):		9.78	(d,	J	=	8.2	Hz,	2H),	8.53	(d,	J	
=	8.0	Hz,	2H),	8.47	(d,	J	=	8.2	Hz,	2H),	8.41‐8.39	(m,	2H),	8.09‐7.99	(m,	4H),	7.86	(d,	J	
=	5.1	Hz,	2H),	7.79‐7.72	(m,	4H),	7.34‐7.28	(m,	4H),	2.16,	(s,	6H).	13C	NMR	(CD3CN):		
169.73,	 158.67,	 158.50,	 154.12,	 152.99,	 152.67,	 143.97,	 140.32,	 139.08,	 138.89,	
135.25,	133.23,	130.57,	129.63,	129.50,	128.60,	128.50,	125.66,	125.55,	26.48.	ESI	
MS	calcd	for	C40H30N8Ru	[M]+724.16,	[M]2+	362.1	found	[M]+723.3,	[M]2+362.1.Purity	
by	 HPLC:	 97.4%	 by	 area.	 UV/Vis	 (MeCN)	 ε:	 284	 nm	 (88900),	 325	 (23600),	 352	
(18900),	450	(14100).		
Ru(bpy)2biq,	GL011:	
Yield:	772.4	mg	(99%).	1H	NMR	(CD3CN,	400	MHz):	8.96	(d,	J	=	8.8	Hz,	2H),	8.78	(dd,	
J	=	8.4,	1.1	Hz,	2H),	8.72	(d,	J	=	8.8	Hz,	2H),	8.65	(dd,	J	=	8.2,	1.1	Hz,	2H),	8.39	(dd,	J	=	
5.3,	1.1	Hz,	2H),	8.29	(q,	J	=	8.9	Hz,	4H),	8.01‐7.98	(m,	4H),	7.91	(d,	J	=	5.3	Hz,	1H),	
7.89	(d,	J	=	5.3	Hz,	1H),	7.64	(d,	J	=	5.5	Hz,	2H),	7.62	(d,	J	=	5.5	Hz,	1H),	7.47	(td,	J	=	
7.9,	 0.9	 Hz,	 2H),	 7.11	 (d,	 J	 =	 8.8	 Hz,	 2H),	 7.05‐7.01	 (m,	 2H).	 13C	 NMR	 (CD3CN):	 	
161.95,	 1588.69,	 154.08,	 152.15,	 149.24,	 148.54,	 140.36,	 138.49,	 138.29,	 132.36,	
132.14,	 132.00,	 130.57,	 130.10,	 1129.98,	 129.27,	 129.14,	 127.22,	 126.89,	 125.73,	
122.08.	ESI	MS	calcd	for	C42H28N6Ru	[M]+718.14,	[M]2+	359.1,	found	[M]+718.3,	[M]‐
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2+359.	 Purity	 by	 HPLC:	 99.9	 %	 by	 area.UV/Vis	 (MeCN)	 ε:	 218	 nm	 (78000),	 338	
(28400),	378	(19300),	440	(8300),	525	(8300).		
Ru(bpy)2‐2,2’‐biq‐4,4’‐dca,	GL013	
ESI	MS	calcd	for	C40H28N6O4Ru	[M]+758.12,	[M]2+	379.1	found	[M]+757.3,	[M]2+379.0.	
Ru(bpy)2bathocuprione,	GL014	
Yield:	607.8	mg	(98.2	%).	1H	NMR	(CD3CN,	400	MHz):	8.61	(d,	J	=	8.0	Hz,	2H),	8.54	
(d,	J	=	8.2	Hz,	2H),	8.10	(td,	J	=	7.9,	1.1	Hz,	2H),	8.04‐7.98	(m,	4H),	7.88	(d,	J	=	5.5	Hz,	
2H),	7.82	(d,	J	=	5.3	Hz,	2H),	7.61‐7.52	(m,	12H),	7.42	(t,	J	=	7.0	Hz,	2H),	7.34	(t,	J	=	6.9	
Hz,	 2H),	 2.01	 (s,	 6H).	 13C	NMR	 (CD3CN):	 167.48,	 158.73,	 158.47,	 153.96,	 152.86,	
150.51,	 150.33,	 138.89,	 138.72,	 136.85,	 130.77,	 130.62,	 130.12,	 128.88,	 128.51,	
128.43,	 128.35,	 125.86,	 125.56,	 125.47,	 26.47.16ESI	 MS	 calcd	 for	 C46H36N6Ru	 [M]‐
+774.2,	 [M]2+	 387.1,found	 [M]+773.3,	 [M]2+387.1.Purity	 by	 HPLC:	 95.0%	 by	
area.UV/Vis	(MeCN)	ε:290	(74100),	454	(15600).		
Ru(dmphen)2‐8HQ,	GL018:	
Yield:55	mg	(24%).	1H	NMR	(CD3CN,	400	MHz):	8.51‐8.44	(m,	2H),	8.30	(d,	J	=	8.4	
Hz,	1H),	8.19‐7.97	(m,	5H),	7.81‐7.74	(m,	1H),	7.69	(d,	J	=	8.2	Hz,	1H),	7.61	(J	=	8.2	
Hz),	7.35	(dd,	J	=	8.4,	2.9	Hz,	2H),	7.09	(t,	J	=	8.0	Hz,	1H),	6.72‐6.64	(m,	3H),	6.25	(d,	J	
=	8.0	Hz,	1H).	13C	NMR	(CD3CN):		169.81,	169.31,	169.00,	168.78,	167.87,	167.53,	
167.43,	 166.80,	 160.28,	 160.27,	 152.13,	 152.05,	 151.35,	 151.19,	 149.95,	 149.53,	
149.02,	 147.06,	 136.59,	 136.47,	 136.43,	 135.95,	 135.52,	 130.49,	 130.38,	 130.30,	
129.99,	127.81,	127.59,	127.52,	127.41,	126.10,	126.07,	26.311,	26.27,	25.04,	24.57.	
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ESI	MS	calcd	for	C37H30N5ORu	[M]+662.15,	 found	[M]+662.1.Purity	by	HPLC:	99.9%	
by	area.UV/Vis	(dH2O)	ε:	224	(64700),	268	(52000),	450	(8100),	497	(8800),	620	
(9900).		
Ru(dmphen)2‐2Me8HQ,	GL019:	
Yield:	96	mg	(58	%).	1H	NMR	(CD3CN,	400	MHz):		8.40‐8.36	(m,	3H),	8.29	(d,	J	=	8.4	
Hz,	1H),	8.23	(d,	J	=	8.2	Hz,	1H),	8.10‐8.02	(m,	5H),	7.88	(s,	1H),	7.75	(d,	J	=	8.6	Hz,	
1H),	7.69‐7.64	(m,	2H),	7.44	(d,	J	=	8.2	Hz,	1H),	7.38	(d,	J	=	8.2	Hz,	2H),	7.00	(t,	J	=	7.8	
Hz,	1H),	6.66	(d,	J	=	8.6	Hz,	1H),	6.60	(d,	J	=	7.8	Hz,	1H),	6.16	(d,	J	=	7.8	Hz,	1H),	2.24	
(s,	3H).	13C	NMR	(CD3CN,	400	MHz):	170.51,	168.99,	168.93,	168.76,	166.66,	161.79,	
160.31,	 160.28,	 160.25,	 160.25,	 160.24,	 154.79,	 151.79,	 151.72,	 146.52,	 137.94,	
136.66,	 136.55,	 136.21,	 135.77,	 130.33,	 130.21,	 129.97,	 129.90,	 129.85,	 129.13,	
127.72,	 127.7,	 127.60,	 127.36,	 127.20,	 127.13,	 126.81,26.64,	 26.38,	 24.67,	 24.66,	
24.03.	ESI	MS	calcd	for	C38H32N5ORu	[M]+676.17,	found	[M]+676.1.	Purity	by	HPLC:	
97.0%	by	area.	UV/Vis	(MeCN)	ε:	225	nm	(62500),	272	(56400),	500	(8800).		
Ru(bpy)2dpq,	GL021:	
Yield:	237	mg	(66	%).	1H	NMR	(CD3CN,	400	MHz):		9.55	(d,	J	=	8.2	Hz,	2H),	9.23	(sd,	
J	=	0.6	Hz,	2H),	8.56	(dd,	J	=	7.8,	7.8	Hz,	6H),	8.22	(dd,	J	=	5.3,	0.6	Hz,	2H),	8.14	(t,	J	=	
7.8	Hz,	2H),	8.03	(t,	J	=	7.6	Hz,	2H),	7.92‐7.87	(m,	4H),	7.68	(d,	J	=	5.6	Hz,	2H).	 	13C	
NMR	 (CD3CN):	 	 158.86,	 158.61,	 155.34,	 153.75,	 153.70,	 153.64,	 153.61,	 150.89,	
147.37,	 141.45,	 139.60,	 139.49,	 134.93,	 131.83,	 129.27,	 129.21,	 129.11,	 129.06,	
128.74,	125.96,	125.89.16	ESI	MS	calcd	for	C34H324N8Ru	[M]+646.12,	found	[M]+645.9.	
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Purity	by	HPLC:	95.4%	by	area.	UV/Vis	(MeCN)	ε:256	nm	(53600),	289	(55900),	449	
(15100).		
Ru(dmphen)2bpy,	GL022:	
Yield:	98	mg	(20	%).	1H	NMR	(CD3CN,	400	MHz):	8.66	(d,	J	=	8.24	Hz,	2H),	8.33	(d,	J	
=	8.42	Hz,	2H),	8.25	(d,	J	=	879	Hz,	2H),	8.18	(d,	J	=	8.24	Hz,	2H),	8.11	(d,	J	=	8.42	Hz,	
2H),	7.83‐7.75	(m,	4H)	7.41	(d,	J	=	8.2	Hz,	2H),	7.03	(d,	J	=	5.86	Hz,	2H),	6.99‐6.95	(m,	
2H),	 2.16	 (s,	 12H).	 13C	 NMR	 (CD3CN):	 	 169.68,	 167.74,	 158.96,	 153.04,	 150.42,	
149.39,	 138.98,	 138.86,	 137.82,	 131.06,	 130.96,	 128.51,	 128.37,	 128.23,	 127.96,	
127.62,	124.90,	26.85,	25.77.		ESI	MS	calcd	for	C38H32N6Ru	[M]+674.17,	[M]2+	337.1,	
found	[M]+673.2,	[M]2+337.0.	Purity	by	HPLC:	94.0%	by	area.	UV/Vis	(MeCN)	ε:	270	
nm	(52100),	290		(29500),	457	(9000).		
Ru(dmphen)2bathophen,	GL023:	
Yield:	101.8	mg	(49	%).	1H	NMR	(CD3CN,	400	MHz):		8.75	(d,	J	=	8.4	Hz,	2H),	8.30	(d,	
J	=	8.0	Hz,	4H),	8.15	(d,	J	=	8.8	Hz,	2H),	7.99	(s,	2H),	8.36	(d,	J	=	8.4	Hz,	2H),	7.56‐7.55	
(m,	 6H),	 7.46‐7.44	 (m,	 6H),	 7.32‐7.28	 (m,	 4H),	 2.02	 (s,	 12H).	 13C	NMR	 (CD3CN):		
168.72,	 166.96,	 152.53,	 149.46,	 149.19,	 148.95,	 148.32,	 137.96,	 136.74,	 135.29,	
130.19,	 129.98,	 129.74,	 129.72,	 129.06,	 128.30,	 127.43,	 127.31,	 127.28,	 126.59,	
125.89,	 125.27,	 26.14,	 24.84.	 ESI	MS	 calcd	 for	 C52H41N6Ru	 [M]+851.24,	 found	 [M]‐
+424.8.	 Purity	 by	 HPLC:	 99.9%	 by	 area.	 UV/Vis	 (MeCN)	 ε:	 220	 nm	 (82300),	 270	
(80100),	470	(16700).	
Ru(dmphen)2dqp,	GL039:	
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Yield:		101.8	mg	(49	%).	1H	NMR	(CD3CN,	400	MHz):		8.73	(d,	J	=	8.4	Hz,	2H),	8.42‐
8.39	(m,	2H),	8.31‐8.24	(m,	5H)	8.12	(d,	J	=	8.8	Hz,	2H),	8.06‐8.05	(m,	2H),	7.83	(d,	J	=	
8.4	 Hz,	 2H),	 7.38‐7.33	 (m,	 5H),	 7.22	 (d,	 J	 =	 8.2	 Hz,	 2H),	 2.16	 (s,	 12H).	 13C	 NMR	
(CD3CN):		169.81,	167.92,	154.09,	140.52,	149.37,	149.34,	139.01,	138.20,	137.63,	
131.00,	129.01,	128.51,	128.29,	128.23,	127.52,	126.17,	26.88,	25.88.16	ESI	MS	calcd	
for	 C42H432N8Ru	 [M]+750.18,	 [M]2+	 375.1	 found	 [M]+749.8,	 [M]2+375.0.	 Purity	 by	
HPLC:	98.1%	by	area.	UV/Vis	(MeCN)	ε:	224	nm	(79900),	268	(79400),	459	(14900).		
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Table	2.1:	Ligand	structures	used	in	complexes	with	corresponding	acronyms	
Ligand	Structure	 Chemical	Name	 Acronym	
2,2’‐bipyridine	 bpy	
	
6,6’‐dimethyl‐2,2’‐
bipyridine	
dmbpy	
1,10‐phenanthroline	 phen	
2,9‐dimethyl‐1,10’‐
phenanthroline	
dmphen	
dipyrido[3,2‐f:2’,3’‐h‐
quinoxaline]	
dpq	
dimethyl‐dipyrido[3,2‐
f:2’,3’‐h‐quinoxaline]	
dmdpq	
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Table	2.1	cont):	Ligand	structures	used	in	complexes	with	corresponding	acronyms	
Ligand	Structure	 Chemical	Name	 Acronym	
dipyrido[3,2‐2',3'‐
c]phenazine	
dppz	
	
dimethyl‐dipyrido[3,2‐
~:2',3'‐c]phenazine	
dmdppz	
4,7‐diphenyl‐1,10‐
phenanthroline	
bp	
2,9‐dimethyl‐4,7‐
diphenyl‐1,10‐
phenanthroline	
bc	
4,7‐diphenyl‐sulfonate‐
1,10‐phenanthroline	
bpds	
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Table	2.1	cont):	Ligand	structures	used	in	complexes	with	corresponding	acronyms	
Ligand	Structure	 Chemical	Name	 Acronym	
2,9‐dimethyl‐4,7‐
diphenyl‐sulfonate‐1,10‐
phenanthroline	
bcds	
2,2’‐biquinoline	 biq	
8‐hydroxyquinoline	 8HQ	
2‐methyl‐8‐
hydroxyquinoline	
2Me8HQ	
3,3‐dicarboxylic	acid‐2,2‐
biquinoline	
2,2’‐biq‐3,3’dca	
	
2‐phenyl‐pyridine	 cyclobpy	
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Table	2.1	cont):	Ligand	structures	used	in	complexes	with	corresponding	acronyms	
Ligand	Structure	 Chemical	Name	 Acronym	
7,8‐benzoquinoline	 cyclophen	
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Table	2.2:	Complex	structures	with	corresponding	code	
Complex	Structure	 Code	
GL001	
	
GL002	
GL003	
GL004	
GL005	
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Table	2.2	(cont.):	Complex	structures	with	corresponding	code	
Complex	Structure	 Code	
GL006	
GL007	
GL008	
	
GL009	
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Table	2.2	(cont.):	Complex	structures	with	corresponding	code	
	
	
Complex	Structure	 Code	
GL010	
	
GL011	
GL013	
GL014	
GL018	
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Table	2.2	(cont.):	Complex	structures	with	corresponding	code	
Complex	Structure	 Code	
GL019	
GL021	
GL022	
GL023	
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Table	2.2	(cont.):	Complex	structures	with	corresponding	code	
Complex	Structure	 Code	
GL024	
	
GL034	
GL035	
GL039	
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Purity	of	Synthesized	Complexes	by	HPLC	
Chloride	salts	of	the	ruthenium	complexes	were	injected	on	an	Agilent	1100	Series	
HPLC	 equipped	with	 a	model	 G1311A	 quaternary	 pump,	 G1315B	UV	 diode	 array	
detector	 and	 Chemstation	 software	 version	 B.01.03.	 Chromatographic	 conditions	
were	optimized	on	a	Column	Technologies	Inc.	C18,	120	Å	(250	mm	x	4.6	mm	inner	
diameter,	5	μm)	fitted	with	a	Phenomenex	C18	(4	mm	x	3	mm)	guard	column.	The	
detection	wavelength	was	 280	 nm.	Mobile	 phases	 used	were	 0.1%	 formic	 acid	 in	
dH2O	and	0.1%	formic	acid	in	HPLC	grade	acetonitrile.	See	table	below	for	gradient	
used.		
Table	2.3:	HPLC	gradient	used	to	test	purity	of	synthesized	ruthenium	complexes	
Time	(minutes)	 0.1%	formic	in	dH2O	 0.1	%	formic	in	MeCN	
0	 98	 2	
2	 95	 5	
5	 70	 30	
15	 70	 30	
20	 40	 60	
30	 5	 95	
35	 98	 2	
40	 98	 2	
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Chapter	3.	 	Photochemisty	of	Ruthenium	Complexes:	Characterization	by	UV‐
Vis	Spectroscopy	and	Mass	Spectrometry	
1.	Introduction	
	Successful	 PDT	 complexes	 should	 efficiently	 produce	 the	 desired	 active	
species	upon	light	activation,	but	not	react	so	quickly	under	ambient	light	conditions	
as	 to	 inhibit	 administration	 of	 the	 drug.	 Moderate	 light	 stability	 is	 required	 to	
ensure	 that	 the	 product	 can	 be	 efficiently	 handled	 and	 transferred	 by	 medical	
personnel	 to	 the	 patient,	 and	 upon	 light	 activation,	 provide	 the	 desired	 cytotoxic	
product.	However,	the	complexes	have	to	react	sufficiently	quickly	for	the	patient	to	
get	an	appropriate	 light	dose	 in	a	short	 time	 to	be	medically	useful.	Photoejection	
experiments	 of	 the	 complexes	 were	 monitored	 by	 UV‐Vis	 to	 observe	 the	 rate	 of	
conversion	 of	 ruthenium	 complex	 reactants	 to	 products.	 Mass	 spectrometry	 was	
used	to	characterize	the	photochemical	products	of	the	reactions.	This	provides	the	
identity	of	the	active	species	that	is	responsible	for	the	biological	effects	observed	in	
Chapters	4	and	5.	
Ruthenium	complexes	 that	are	not	 sterically	 strained	do	not	exhibit	photo‐
degradation	 due	 to	 the	 low	 efficiency	 of	 population	 of	 the	 3MC	 excited	 state	 after	
photoexcitation	 at	 room	 or	 physiological	 temperatures	 (22	 or	 37	 ˚C).	 	 These	
compounds	are	stable	 in	 the	presence	of	 light.	Several	unstrained	complexes	were	
synthesized	to	act	as	control	compounds.	Alternatively,	several	strained	complexes	
have	 been	 synthesized	 that	 are	 capable	 of	 populating	 the	 3MC	 state,	 resulting	 in	
ligand	ejection	upon	light	activation	(see	Chapter	2.2).		
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2	Photoejection	Experiments	Monitored	by	UV‐Vis	Spectroscopy	
UV‐Vis	 spectroscopy	was	used	 to	observe	 the	absorbance	properties	of	 the	
synthesized	 ruthenium	 complexes.	 Due	 to	 the	 number	 of	 complexes	 analyzed	 for	
this	study,	all	absorption	profile	figures	are	included	at	the	end	of	the	chapter.		
	 Figure	3.1	shows	the	typical	absorbance	spectra	of	ruthenium	complexes	that	
are	 stable	 in	 the	 presence	 of	 light.	 Complexes	 GL004,	 009,	 and	 021	 display	 an	
absorbance	maximum	at	~450	nm,	and	the	absorption	spectra	do	not	change	upon	
exposure	to	light.		
In	 contrast,	 sterically	 hindered,	 octahedral	 ruthenium	 complexes	 can	
successfully	 shuttle	 electrons	 into	 the	 3MC	 excited	 state	with	 blue	 light	 activation	
(see	Figure	2.2).	Exposure	to	blue	light	was	punctuated	by	periodic	UV‐Vis	scans	in	
order	 to	 track	 the	 conversion	 of	 the	 starting	 complex	 to	 the	 photoproduct.	 	 The	
difference	 in	absorbance	at	~495	nm	vs	~410	nm	(A495‐410)	were	plotted	against	
time	 (minutes)	 to	 show	 the	 time	 dependence	 for	 the	 photochemical	 reactions.	
Curves	were	fit	and	kinetic	half‐lives	were	determined	with	a	‘one	phase	association’	
equation	to	yield	the	calculated	half‐life	(t1/2)	of	the	complex	using	Prism	software.	
Spectral	changes	observed	for	photo‐ejecting	complexes	are	displayed	in	Figure	3.2	
and	t1/2	values	are	summarized	in	Table	3.1.		
GL002	displays	a	good	balance	of	light	activated	activity,	with	a	near‐optimal	
half‐life	 of	 1.9	 minutes	 observed	 for	 the	 complex.	 The	 complex	 employs	 the	
Ru(bpy)2	backbone	and	ejects	the	strained	6,6’‐dimethyl‐2,2’‐bipyridine	ligand	(see	
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Table	3.2).	Structural	differences	in	the	sterically	strained	ligand	produce	different	
ejection	 profiles.	 For	 example,	 GL007	 has	 a	 half‐life	 of	 112.8	minutes,	 ~60	 times	
slower	 than	GL002	(see	Table	3.1).	GL007	does	not	 incorporate	 the	6,6’‐dimethyl‐
2,2’‐bipyridine	 ligand;	 instead,	 it	 contains	 2,9‐dimethyl‐1,10‐phenanthroline	 (see	
Table	 2.1).	 An	 apparent	 trend	 is	 that	 complexes	 utilizing	 the	 6,6’‐dimethyl‐2,2’‐
bipyridine	 ligand	 tend	 to	 degrade	 faster	 than	 fused	 ring	 systems	 such	 as	 1,10‐
phenanthroline.	 Increasing	 the	 planar	 surface	 in	 the	 fused	 ligands	 by	 adding	 a	
dmdpq	(complex	GL003)	or	dmdppz	(complex	GL010)	ligand	(see	Table	2.1)	to	the	
Ru(bpy)2	 scaffold	 further	 supports	 this	 observation.	 GL003	 has	 a	 long	 half‐life	 of	
60.9	minutes,	and	GL010	has	a	half‐life	greater	than	6	hours.	In	order	to	obtain	an	
ejection	 profile	 for	 GL010,	 intense	white	 light	was	 employed	 instead	 of	 blue	 light	
used	 in	 other	 studies.	 Under	 these	 conditions,	 the	 half‐life	 of	 the	 complex	 is	 20.5	
minutes	(see	Table	3.1).		
The	differences	 in	photoreaction	half‐lives	provide	useful	guidelines	 for	 the	
development	of	these	complexes,	and	it	is	clear	that	strained	bipyridine	ligands	eject	
faster	than	fused	ring	systems	incorporated	in	complexes	such	as	GL003,	007,	010	
(see	Table	3.3).	Recoordination	of	more	rigid	ligands	such	as	dmphen,	dmdpq,	and	
dmdppz	 (see	 Table	 2.1)	 appears	 to	 occur	 readily,	 hindering	 the	 complete	 photo‐
dissociation	 of	 the	 ligand	 and	 resulting	 in	 longer	 half	 lives	 (see	 Table	 3.1).	 The	
enhanced	 photoejection	 rate	 for	 complexes	 of	 6,6’‐dimethyl‐2,2’‐bipyridine	 is	
thought	to	be	due	to	the	ability	of	the	ligand	to	rotate	freely	around	the	C2‐C2’	bond,	
thwarting	recoordination	and	resulting	in	ligand	loss.		
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The	half‐lives	of	the	ruthenium	complexes	are	summarized	in	Table	3.1.	The	
fastest	 ejecting	 complexes	 are	 the	 ones	 utilizing	 the	 2,2’‐6,6’‐dimethyl‐bipyridine	
ligand.	Complex	GL002	and	005	have	half‐lives	of	1.9	and	0.6	minutes	respectively.	
Moving	the	methyl	group	around	the	bipyridine	ligand	to	the	3,3’	positions	provides	
a	 different	 type	 of	 steric	 clash	 (“backside	 clash”)	 seen	 in	 complex	 GL006,	
significantly	increasing	the	t1/2	to	230	minutes.		
	 The	 ejection	kinetics	 for	GL002	are	~50	 fold	 faster	 than	GL011,	 a	 complex	
containing	a	biquinoline	ligand.	It	was	thought	that	the	addition	of	a	phenyl	ring	to	
the	2,2‐bipyridine	motif	 to	make	the	biquinoline	 ligand	would	provide	more	steric	
clash	and	thus	a	faster	photoactive	complex.		This	was	not	observed,	and	is	thought	
that	the	size	of	the	six	methyl	hydrogens	provides	more	steric	clash	compared	to	the	
bulk	of	the	biquinoline	ligand	with	two	benzyl	hydrogens.	
To	 observe	 the	 effect	 of	 electron	withdrawing	 groups	 on	 ejection	 kinetics,	
GL008	 and	 014	 were	 synthesized.	 Both	 compounds	 contain	 the	 same	 Ru(bpy)2	
backbone	and	only	differ	by	the	addition	of	sulfonate	groups	to	complex	GL008	(see	
Table	2.2).	A	six‐fold	increase	 in	the	ejection	kinetics	was	observed	for	GL008	and	
014,	 with	 t1/2	 values	 of	 12.6	 and	 59.7	 minutes	 respectively	 (see	 Table	 3.1).	 The	
addition	of	 these	 groups	may	have	 a	negative	 effect	 on	 the	 ability	of	 the	nitrogen	
atoms	 to	 efficiently	 donate	 their	 electrons	 to	 the	 ruthenium	 center	 and	 could	 be	
another	mechanism	by	which	the	ejection	kinetics	can	be	tuned.	
However,	 addition	 of	 electron	 withdrawing	 carboxylic	 acid	 groups	 to	 the	
biquinoline	 ligand	 appear	 to	 have	 the	 opposite	 effect	when	 comparing	 complexes	
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GL011	and	013	(see	Table	2.2).	Complex	GL013,	contains	carboxylic	acid	groups	at	
the	 4,4’	 positions	 and	 displays	 the	 slowest	 ejection	 kinetics	 observed	 under	 blue	
light,	with	a	 t1/2	of	greater	 than	six	hours	(see	Table	3.1).	 	 Intense	white	 light	was	
also	 used	 on	 this	 complex	 to	 get	 an	 ejection	 profile	 in	 a	 timely	 manner.	 Under	
intense	white	light,	the	observed	t1/2	was	242.3	minutes.		Reduction	of	the	electron	
donating	ability	of	the	nitrogen	atoms	through	the	addition	of	electron	withdrawing	
carboxylic	groups	is	not	observed	in	complex	GL013.	Additional	complexes	with	the	
same	 bis‐1,10‐phenanthroline	 backbone	 containing	 ligands	 such	 as	 6,6’‐dimethyl‐
2,2’‐bipyridine	 with	 carboxylic	 acid	 groups	 at	 the	 4,4’	 position	 should	 be	
synthesized	 to	 understand	 why	 complex	 GL011	 has	 faster	 ejection	 kinetics	 than	
GL013.		
The	 addition	of	 4,7‐diphenyl	 groups	 to	 the	1,10‐phenanthroline	 ligand	also	
appears	to	hinder	dissociation.		A	three	fold	kinetic	difference	(5.4	and	15.2	minutes	
respectively)	 is	observed	 in	the	half‐lives	of	GL022	and	023.	 It	 is	possible	 that	 the	
addition	 of	 the	 para‐electron	 donating	 phenyl	 groups	 stabilize	 the	 nitrogen‐
ruthenium	bond,	hindering	photo‐dissociation.	The	6,6‐dimethyl‐4,7‐diphenyl‐2,2’‐
bipyridine	analogue	containing	complexes	that	contain	the	electron	donating	phenyl	
groups	 at	 the	meta	 and	 ortho	 positions	 could	 be	 synthesized	 to	 observe	 how	 the	
position	of	the	electron	withdrawing	groups	affects	the	kinetic	activity.	
	 Complexes	containing	different	backbones	have	also	been	prepared.	GL018,	
019,	022,	and	023	contain	the	Ru(dmphen)2	backbone,	and	have	different	ejection	
profiles.	 	 The	 quinoline	 containing	 compounds	 GL018	 and	 019	 display	 different	
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kinetics,	even	though	the	only	difference	between	the	complexes	is	the	addition	of	a	
methyl	 group	 at	 the	 two‐position	 on	 the	 quinoline	 ligand.	 Modeling	 may	 be	
necessary	 to	understand	why	GL018	ejects	 faster,	and	produces	a	mix	of	products	
(see	 Table	 3.2)	 as	 opposed	 to	 the	 more	 sterically	 hindered	 GL019,	 which	 ejects	
slower	and	produces	one	photo‐dissociation	product.		
Very	 reactive	 complexes	 containing	 two	 sterically	hindered	 ligands	 such	as	
the	Ru(dmbpy)2	starting	material	with	2,2’‐bipyridine	as	well	as	the	slower	ejecting	
dmdpq	ligand	were	synthesized.	Products	of	these	reactions	were	confirmed	by	the	
absence	 of	 an	 emissive	 spot	 on	 thin	 layer	 chromatography	 and	 by	 mass	
spectrometry	 of	 the	 reaction	mixture,	 but	 the	 compounds	 readily	 degraded	 upon	
flash	 chromatography	 purification	 and	 were	 unable	 to	 be	 characterized.	 This	
showed	 that	 the	Ru(dmbpy)2	backbone	 is	 too	 reactive	 for	 the	generation	of	useful	
complexes	for	PDT	applications.	
In	order	to	tune	the	absorption	profiles	of	 the	metal	complexes,	a	synthetic	
approach	was	attempted	 to	generate	 complexes	 that	absorb	closer	 to	 the	 infrared	
region	 of	 the	 spectrum.	 Compounds	 that	 readily	 degrade	 to	 their	 corresponding	
activated	 species	 utilizing	 longer	 wavelength	 light	 are	 desirable	 as	 the	 longer	
wavelength	light	is	capable	of	penetrating	deeper	tissues.	The	Ru(phen)2Cl2	scaffold	
coupled	 with	 the	 biquinoline	 ligand	 provides	 an	 example	 of	 the	 red	 shift	 sought	
(GL011,	Figure	3.2).	The	biquinoline	ligand	was	selected	for	its	extended	pi	system,	
as	it	should	reduce	the	MLCT	band	energy	(see	Figure	2.2).	As	expected,	a	red	shift	
in	absorbance	maxima	from	the	typical	450	nm	to	510	nm	is	observed	in	complex	
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GL011.	 The	 strain	 from	 the	 additional	 ring	 on	 the	 biquinoline	 ligand	 produces	 a	
photoejecting	complex	(see	Table	3.2).			
The	desired	red	shift	was	also	observed	utilizing	the	cyclometallated	ligands	
2‐phenylpyridine	 and	 7,8‐benzoquinoline	 coupled	 with	 the	 Ru(bpy)2	 backbone	
shown	 in	 complexes	 GL034	 and	 035	 (Figure	 3.1)	 Cyclometallated	 systems	 GL034	
and	 035	 are	 significantly	 red	 shifted,	 as	 expected,	 with	 observed	 absorbance	
maxima	 centered	 at	 550	 nm.	However,	 these	 compounds	 do	 not	 eject	 as	 they	 are	
unstrained	and	are	unable	to	populate	the	3MC	excited	state.	As	a	result,	no	spectral	
change	is	observed	upon	exposure	to	light.	Synthesis	of	cyclometallated	complexes	
with	the	strained	Ru(dmphen)2	backbone	should	be	performed	to	obtain	the	desired	
red	shift	while	producing	a	photo‐active	species	capable	of	photo‐binding	DNA.		
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Figure	3.1:	Non‐photoejecting	Complexes	
GL004	
GL009	
GL024	
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Figure	3.1:	Non‐photoejecting	Complexes	(cont.)	
GL034	
	
GL035	
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Figure	3.2:	Photo‐ejecting	Complexes	
GL002	
GL003	
GL005	
GL006	
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Figure	3.2:	Photo‐ejecting	Complexes	(cont.)	
GL007	
GL008	
GL010	–	white	light	curve	shown	
GL011	
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Figure	3.2:	Photo‐ejecting	Complexes	(cont.)	
GL013	
GL014	
GL018	
GL019	
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Figure	3.2:	Photo‐ejecting	Complexes	(cont.)	
GL022	
GL023	
GL039	
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Table 3.1:  Complex t1/2 values 
Complex Code Complex t1/2 (minutes) 
GL002 Ru(bpy)2dmbpy 1.9 
GL003 Ru(bpy)2dmdpq 60.9 
GL005 Ru(bpds)2dmbpy 0.6 
GL006 Ru(bpy)2-3,3’dmbpy 230 
GL007 Ru(bpy)2dmphen 112.8 
GL008 Ru(bpy)2bcds 12.6 
GL010 Ru(bpy)2dmdppz >6hrs/20.5* 
GL011 Ru(phen)2biq 89.2 
GL013 Ru(bpy)2-2,2’biq-4,4’-dca >8hrs/242.3* 
GL014 Ru(bpy)2bc 59.7 
GL018 Ru(dmphen)2-8HQ 17.3 
GL019 Ru(dmphen)2-8H-2MeQ 32.7 
GL022 Ru(dmphen)2bpy 5.4 
GL023 Ru(dmphen)2bp 15.2 
GL039 Ru(dmphen)2dpq 3.2 
*white light used 
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2		Active	Species	Determined	by	ESI‐Mass	Spectrometry	
Mass	 spec	 experiments	 were	 carried	 out	 to	 determine	 the	 identity	 of	 the	
ejected	 ligand	 and	 active	 ruthenium	 species	produced	when	 the	Ru(II)	 complexes	
were	light	activated.		Strained	octahedral	complexes	with	accessible	3MC	states	(see	
Figure	2.2)	were	analyzed	at	micromolar	concentrations	 to	mimic	conditions	used	
for	in	vitro	and	in	vivo	experiments	(see	Chapters	4	and	5).	The	expected	masses	of	
the	pure	complexes	were	observed	pre‐exposure,	and	the	light‐activated	ruthenium	
species	and	ejected	 ligand	masses	were	observed	post‐exposure.	 	As	some	 ligands	
are	 observed	 better	 than	 others	 on	 the	 instrument,	 only	 qualitative	 observations	
were	 made	 about	 the	 percent	 abundance	 of	 the	 ejected	 ligands.	 For	 quantitative	
measurements	of	reaction	kinetics,	see	Table	3.1.		
Infusion	 of	 the	 model	 complex	 GL002	 in	 the	 absence	 of	 light	 gives	 the	
expected	masses	 of	 the	 complex	 (M+	=	 743	 and	M2+	=	 299).	 Following	white	 light	
activation,	 infusion	 of	 the	 same	 sample	 gives	 the	 expected,	 ejected	 ligand	 6,6’‐
dimethyl‐2,2’‐bipyridine	(m/z	=	185.0	amu)	as	well	as	the	activated	Ru(bpy)2	(m/z	
=	414)	 species	 capable	of	 cross‐linking	DNA.	The	half‐life	of	GL002	 is	1.9	minutes	
(see	 Table	 3.1)	 and	 complete	 conversion	 of	 reactant	 to	 product	 is	 qualitatively	
observed.	
Complexes	with	 the	 same	Ru(bpy)2	 scaffold	 such	 as	 GL003,	 006,	 007,	 010,	
and	 014	 exhibit	 similar	 ejection	 profiles,	 producing	 the	 more	 sterically	 hindered	
ligand	 and	 giving	 a	 single	 activated	 Ru(bpy)2	 species.	 	 Complexes	 such	 as	 GL003,	
007,	010,	and	014	that	contain	rigid,	fused	ring	ligands	eject	more	slowly	(see	Table	
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2.1),	 resulting	 in	 incomplete	 product	 conversion	with	 two	minutes	 of	 white	 light	
photo‐activation.		
Utilizing	 the	 more	 rigid	 bis‐1,10‐phenathroline	 (m/z	 =	 462)	 backbone	
similarly	yields	the	ejection	of	the	single	biquinoline	ligand	(m/z	=	257)	observed	in	
complex	GL011.		Addition	of	methyl	groups	to	this	more	rigid	backbone	such	as	the	
Ru(bis‐2,9‐dimethyl‐1,10‐phenanthroline)2	 scaffold	displayed	 in	 complexes	GL018,	
019,	 022,	 023,	 and	 039,	 produce	 different	 active	 species.	 GL018	 and	 022	 give	 a	
mixture	of	activated	products	when	exposed	to	light.		Complex	GL018	ejects	the	2,9‐
dimethyl‐1,10‐phenanthroline	 (m/z	 =	 209)	 and	 8‐hydroxyquinoline	 (m/z	 =	 146)	
ligands.	 	Similarly,	complex	GL021	ejects	2,9‐dimethyl‐1,10‐phenanthroline	(m/z	=	
209)	as	well	as	2,2’‐bipyridine	(m/z	=	157).	How	this	mixture	of	activated	products	
affects	 the	cellular	potency	 is	examined	 in	Chapter	5.1.	Complexes	GL023	and	039	
produce	similar	active	species	through	the	ejection	of	the	dmphen	ligand.		
Complexes	GL019	differs	from	GL018	only	by	the	addition	of	a	methyl	group	
at	the	two‐position	on	the	8‐hydroxyquinoline	ligand	(see	Table	2.1).	While	GL018	
ejects	 a	mixture	 of	 products,	 GL019	 only	 ejects	 the	 quinoline	 ligand	 (m/z	 =	 160).	
These	 complexes	 have	 similar	 in	vitro	 IC50	results	 (31	 μM,	 see	 Table	 4.1)	 forming	
cross‐links	 to	 DNA.	 In	 addition	 to	 cross‐links,	 GL019	 also	 produces	 single	 strand	
breaks.	Both	complexes	show	potential	as	traditional	chemotherapeutics	(not	 light	
activated)	and	are	potent	on	A549	cells,	showing	nanomolar	IC50’s	(see	Table	5.5).	
For	a	complete	discussion	on	the	activities	of	the	quinoline	complexes,	see	Chapter	
5.1	A549	Growth	Inhibition	Assays.	
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The	 ejection	 properties	 of	 complexes	 with	 different	 overall	 charge	 states	
such	as	GL005	and	008	(overall	charge	=	2‐	and	0	respectively)	were	also	examined	
(see	Table	2.2).		Complex	GL005	was	found	to	eject	the	6,6’‐dimethyl‐2,2’‐bipyridine	
ligand	(m/z	=	185),	while	complex	008	ejected	a	2,2’‐bipyridine	ligand	(m/z	=	157).	
A	summary	of	the	complexes	and	the	ligands	ejected	with	a	qualitative	estimate	of	
the	percent	 conversion	 to	 the	photo‐activated	complex	with	 two	minutes	of	white	
light	are	displayed	in	Table	3.2.	
Table	3.2:	Ejection	products	observed	by	ESI‐MS	
Ruthenium	
Complex	
Code	
Name	 Ejected	ligand	
Estimated	
Percent	
Abundance	of	
Ejected	Ligand	
GL002	 Ru(bpy)2dmbpy	 dmbpy	 100	
GL003	 Ru(bpy)2dmdpq	 dmdpq	 60	
GL005	 Ru(bpds)2dmbpy	 dmbpy	 100	
GL006	 Ru(bpy)2‐3,3’dmbpy	 3,3’dmbpy	 60	
GL007	 Ru(bpy)2dmphen	 dmphen	 40	
GL008	 Ru(bpy)2bcds	
	
bcds	 50	
GL010	 Ru(bpy)2dmdppz	 dmdppq	 90	
GL011	 Ru(phen)2biq	 biq	 50	
GL013	 Ru(bpy)22,2’biq‐3,3’dca	 2,2’biq‐
3,3’dca	
10	
GL014	 Ru(bpy)2bc	 bc	 40	
GL018	 Ru(dmphen)28HQ	 8HQ/dmphen	 60	
GL019	 Ru(dmphen)2‐2‐Me‐8HQ	 2MeHQ	 50	
GL022	 Ru(dmphen)2bpy	 bpy/dmphen	 80	
GL023	 Ru(dmphen)2bp	 dmphen	 50	
GL039	 Ru(dmphen)2dpq	 dmphen	 80	
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3.	Reaction	of	GL002	with	Mixed	Nucleosides	by	ESI‐MS	
	 Cisplatin	is	known	to	preferentially	react	with	the	N7	position	of	guanosine	
(see	Figure	1.1).1	To	a	lesser	extent,	the	complex	also	has	an	affinity	for	the	N1	and	
N7	 positions	 of	 adenosine	 as	 well	 as	 the	 N3	 position	 of	 cytidine.2	 Cisplatin	 has	
limited	 to	 no	 reactivity	with	 thymidine.3	To	 determine	which	 bases	 GL002	 reacts	
with,	a	2:1	ratio	of	GL002:	individual	nucleosides	(guanosine,	adenosine,	cytidine,	or	
thymidine)	 were	 studied	 via	 ESI‐MS.	 Dark	 control	 experiments	 were	 ran	 parallel	
with	light	activated	samples	and	incubated	for	one	hour	before	MS	analysis.	All	dark	
control	samples	displayed	similar	results.	Masses	of	GL002	(M+	m/z	=	597,	M2+	m/z	
=	 298)	 were	 observed	 in	 all	 samples	 with	 the	 individual	 nucleoside	 masses	
(adenosine	m/z	=	268,	thymidine	m/z	=	242,	cytidine	m/z	=	242,	guanosine	m/z	=	
284).	 Infusion	of	 light	activated	 reactions	yielded	 complexes	with	all	 of	 the	bases,	
though	 to	 a	 much	 lesser	 extent	 with	 thymidine.	 The	masses	 observed	 for	 photo‐
activated	GL002	are	the	active	species,	Ru(bpy)2	(m/z	=	414)	and	the	ejected	ligand	
dmbpy	(m/z	=	185).	Reactions	with	adenosine	and	photo‐activated	GL002	rendered	
a	 complex	masses	 of	m/z	=	 680	 (expected	m/z	=	 681),	which	 corresponds	 to	 the	
Ru(bpy)2	 (m/z	 =	 414)	 active	 species	 plus	 adenosine	 (m/z	 =	 268).	 The	 GL002‐
thymidine	complex	was	found	at	very	 low	abundance	(m/z	=	655,	expected	m/z	=	
656).	 Reactions	 with	 GL002‐cytidine	 yielded	 a	 complex	 mass	 of	 m/z	 =	 656	
(expected	657).	Guanosine	produced	the	most	abundant	signal	with	M+1	m/z	=	696	
(expected	697).	This	was	expected	due	to	cisplatin’s	preference	to	the	base.1		
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4.		Reaction	of	GL002	with	Mixed	Nucleosides	by	LC‐MS	
	 To	determine	the	nucleoside	preference	of	GL002,	the	complex	was	activated	
and	added	to	a	mixture	of	the	individual	bases	(A,	C,	T,	G	combined	in	equal	parts),	
and	analyzed	on	the	LC‐ESI	mass	spectrophotometer.	1200	μM	GL002	was	added	to	
the	nucleoside	mixture	 (at	40	μM	per	base)	 following	photoejection	(1:1	complex:	
individual	base)	and	injected.	A	mixed	nucleoside‐only	sample	was	prepared	at	40	
μM	 per	 base	 and	 injected	 to	 serve	 as	 a	 standard	 and	 to	 calculate	 the	 percent	
recovery	of	 the	 individual	bases	 (see	Figure	3.3).	Retention	 times	observed	of	 the	
injected	bases	are:	Cytidine,	13.8	minutes;	Adenosine,	19	minutes;	Guanosine,	19.8	
minutes;	 Thymidine,	 22.1	minutes	 (the	 slight	 shift	 in	 retention	 times	 of	 the	bases	
observed	 upon	 the	 addition	 of	 GL002	 in	 Figure	 3.3b	 is	 due	 to	 inefficient	
equilibration	of	the	column	prior	to	injection.	The	method	should	be	extended	to	60	
minutes,	 returning	 the	 gradient	 to	5%	B	 at	 55	minutes	 to	 allow	adequate	 column	
requilibration	 prior	 to	 subsequent	 injections.	 Complex	 masses	 similar	 to	 those	
found	above	were	observed	with	all	nucleosides	in	low	abundance.	Addition	of	the	
peak	 at	 RT	 =	 22.8	minutes	 contains	 the	mass	 of	 the	 active	 species	 Ru(bpy)2	 plus	
guanosine	(m/z	=	696)	is	displayed	in	Figure	3.3c.	Percent	recovery	was	calculated	
using	 the	 Varian	 MS	 Workstation	 software.	 Preference	 to	 guanosine	 is	 observed	
through	an	8%	loss	of	guanosine	in	the	base:	complex	sample	when	compared	to	the	
standard.		
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Figure	3.3:	 a)	40	μM	mixed	nucleosides	 (peaks	 in	order:	C,	A,	G,	T);	 b)	1:1	GL002	
with	mixed	nucleosides	(C,	A,	G,	002	plus	G,	T;	c)	GL002:	guanosine	observed	masses	
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5.	Light	Titration	of	GL002	monitored	by	ESI‐MS	
In	order	to	determine	the	reactivity	of	GL002	with	light	by	ESI‐MS,	a	photoactivation	
experiment	was	performed	while	 flowing	sample	 into	 the	spectrometer.	This	 light	
titration	experiment	was	 carried	out	using	 the	aforementioned	ESI‐MS	 setup	with	
the	addition	of	a	flashlight	to	provide	a	light	source	to	photo‐activate	the	ruthenium	
complex.	Dual	 ion	monitoring	mode	was	utilized	to	observe	the	dissociation	of	the	
complex.	The	m/z	=	299	ion	corresponds	to	the	unactivated	M2+	complex.	The	m/z	=	
185	 ion	 corresponds	 to	 the	 ejected	 6,6’‐dimethyl‐2,2’‐bipyridine	 ligand.	 The	
isosbestic	point	observed	at	~1.5	minutes	parallels	 the	half‐life	observed	 in	Table	
3.1.	 This	 mass	 screening	 analytical	 technique	 provides	 both	 the	 kinetics	 and	 the	
identity	of	the	active	species	produced	by	the	ruthenium	complexes.	
Figure	3.4:	Light	titration	of	GL002	
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6.	Experimental	
Absorbance	 measurements	 were	 obtained	 using	 an	 Agilent	 8353	 UV‐Vis	
Spectrophotometer	 equipped	 with	 Agilent	 Chemstation	 Version	 B.02.01	 sp1	
software	using	a	1	cm	cuvette.	The	instrument	was	blanked	on	the	solvent	used	in	
the	 specific	 experiment.	Compound	 concentrations	were	 ca.	30	μM,	 and	 the	 initial	
dark	 control	 was	 scanned	 followed	 by	 exposure	 to	 blue	 light	 with	 Dell	 1410X	
projector/200	W	light	source.	Samples	were	placed	12	inches	from	the	light	source.		
Scans	 were	 taken	 periodically	 at	 set	 times	 to	 monitor	 the	 development	 of	 the	
degradation	species	and	active	species	products	until	no	change	in	the	spectra	was	
observed.	Kinetics	were	calculated	using	Prism	software	to	give	photochemical	half‐
lives.	
Mass	 spectrometry	 experiments	 were	 carried	 out	 on	 a	 Varian	 1200L	
Quadrupole	MS/MS	ESI	mass	 spectrometer	equipped	with	Varian	MS	Workstation	
Version	6.42	and	Harvard	Apparatus	Pump	11	syringe	pump.	~1	mg/mL	complexes	
were	prepared	(chloride	salts	in	water/PF6	salts	in	acetonitrile)	and	kept	from	light.		
Micromolar	 solutions	 of	 each	 complex	 were	 infused	 in	 80:20:0.1%	
methanol:water:formic	acid	before	and	after	two	minute	light	exposure	with	a	410	
W	 light	 source	 (see	 Ch.	 5	 In	 vivo	 experimental)	 to	 observe	 the	 initial	 and	 light	
activated	complex	masses.		
Reactions	with	nucleosides:	
	 Guanosine	(cas	118‐00‐3)	was	obtained	from	Alfa	Aesar.	Adenosine	(cas	58‐
61‐7)	and	cytidine	(cas	65‐46‐3)	were	obtained	from	Sigma.	Thymidine	(cas	50‐89‐
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5)	was	obtained	from	TCI.	All	reagents	were	used	without	further	purification.	Stock	
DMSO	 solutions	 of	 the	 individual	 nucleosides	 were	 prepared.	 Mixtures	 of	 the	
individual	 bases	 with	 GL002	 were	 prepared	 at	 1:2	 (150	 μM	 nucleoside:	 300	 μM	
GL002)	 ratios.	 Dark	 control	 samples	 were	 prepared	 through	 the	 addition	 of	 the	
nucleoside	with	 GL002	 and	 protected	 from	 light	wrapped	 in	 aluminum	 foil.	 Light	
activated	samples	were	prepared	through	the	addition	of	the	nucleoside	with	GL002	
and	 placed	 under	 the	 aforementioned	 Dell	 projector	 for	 1	 hour.	 Samples	 were	
infused	in	80:20:0.1%	methanol:water:formic	acid	on	the	previously	mentioned	ESI	
mass	spectrophotometer.	Dark	control	samples	were	infused	under	low	light	room	
conditions	with	the	syringe	wrapped	in	aluminum	foil.		
	 Nucleosides	 used	 are	 described	 above.	 1:1	 GL002	 (1200	 μM):	 nucleoside	
(300	μM	each)	 concentrations	were	used	 to	 obtain	 the	 results.	Using	 stock	DMSO	
solutions	of	 the	nucleosides,	a	mixture	was	prepared	at	300	μM	per	base	and	was	
added	to	photo‐ejected	GL002	in	dH2O	and	allowed	to	incubate	at	37	oC	for	2	hours.	
A	 nucleoside	 only	 sample	was	 prepared	 at	 identical	 concentration	 of	 300	 μM	per	
base	 in	 dH2O	 to	 serve	 as	 a	 standard	 and	 to	 calculate	 percent	 recovery.	 A	 blank	
solution	was	prepared	to	mimic	DMSO	concentrations	in	dH2O.	The	experiment	was	
carried	 out	 with	 the	 previously	mentioned	 ESI	mass	 spectrophotometer	with	 the	
addition	of	the	two	Varian	ProStar	pump	(model	210).	10	μL	were	injected	on	a	C18	
column	 (Column	 Technologies	 Inc.,	 5μm	 120	 A,	 4.5x25	 cm,	 part	 number	
CTI0DS546250)	at	0.25	mLmin‐1	using	the	following	gradient:	
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Table	3.3:	HPLC	gradient	used	for	GL002:mixed	nucleoside	HPLC‐Ms	experiment	
Time	
(minutes)	
0.1	%	Formic	Acid/miliQ‐H2O	 0.1	%	Formic	Acid/MeCN	
0	 95	 5	
2	 95	 5	
18	 70	 30	
22	 70	 30	
35	 5	 95	
38	 5	 95	
39	 95	 5	
53	 100	 0	
55	 100	 0	
	
Light	Titration	of	GL002:	
Micromolar	 solutions	 of	 GL002	 were	 infused	 in	 80:20:0.1%	
MeOH:dH2O:Formic	 Acid	 and	 acquired	 on	 the	 previously	 mentioned	 ESI	 mass	
spectrophotometer.	Sample	was	infused	in	the	dark	and	was	exposed	to	light	with	a	
standard	 Rayovac	 IN2	 flashlight.	 The	 photo‐ejection	 of	 GL002	 was	 observed	
following	m/z	ions	299	(M2+)	and	the	dissociated	ligand	dmbpy	(m/z	=	185).	Curves	
were	generated	using	Prism	software	using	the	‘one	phase	association’	equation.		
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Chapter	4:	In	Vitro	Studies	of	Light‐Activated	Ruthenium	Complexes	
Other	 scientists	 including	Dr.	David	Heidary	and	Erin	Wachter	 contributed	 to	 this	
this	chapter.	
Introduction	
The	 goal	 of	 this	 project	 is	 to	 synthesize	 photoactive	 complexes	 that	 form	
cross‐links	 with	 DNA,	 leading	 to	 cell	 death.	 A	 distinction	 between	 dark	 and	 light	
activated	 DNA	 damage	 is	 required	 for	 successful	 photodynamic	 therapy.	 Dark	
toxicity	should	be	minimized	in	order	to	avoid	unnecessary	damage	to	the	healthy	
tissue	surrounding	the	area	to	be	treated.	In	order	to	test	these	effects,	in	vitro	DNA	
damage	studies	were	performed	using	the	pUC19	plasmid	DNA.	
4.1.	DNA	Damage	Studies	by	Gel	Electrophoresis	
In	 vitro	 gel	 electrophoresis	 experiments	 were	 carried	 out	 with	 pUC19	
plasmid	 DNA	 to	 analyze	 the	 DNA	 damage	 caused	 by	 the	 synthesized	 ruthenium	
complexes	 either	 in	 the	 dark	 or	 through	 light	 activation.	 The	 activity	 of	 the	
complexes	 was	 compared	 to	 the	 chemotherapeutic	 cisplatin,	 the	 prototypical	
inorganic	 DNA	 damaging	 agent.	 Cisplatin	 cross‐links	 DNA,	 which	 results	 in	 the	
induction	 of	 cell	 death,	 but	 a	 significant	 drawback	 is	 that	 it	 does	 not	 distinguish	
between	 healthy	 and	 cancerous	 cells.1	 Unwinding	 of	 platinated	 pUC19	 DNA	 is	
observed	 through	 the	 decreased	 mobility	 of	 the	 DNA	 in	 the	 agarose	 gel	 with	
increasing	cisplatin	concentrations	 (see	Figure	4.1).	The	decreased	mobility	of	 the	
DNA	is	a	result	of	increasing	platination	of	the	DNA	with	increasing	concentrations	
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of	cisplatin.		An	IC50	value	of	cisplatin	was	determined	based	on	the	concentration	of	
the	compound	that	resulted	 in	 the	pUC19	plasmid	existing	 in	a	state	where	 it	was	
unwound	 by	 50%.	 This	 was	 observed	 at	 31	 μM	 with	 the	 complete	 unwinding	
occurring	at	100	μM.		
Figure	4.1:	Cisplatin	with	pUC19	DNA	
	
	 To	determine	 the	 type	of	DNA	 interaction	or	damage	 that	could	occur	with	
the	ruthenium	complexes,	DNA	damage	was	induced	with	other	control	compounds	
and	 agents.	 The	 metal	 complex	 copper	 phenanthroline	 (Cu(phen)2)	 is	 known	 to	
produce	 single	 strand	 breaks	 by	 nicking	 the	 DNA	 forming	 the	 relaxed	 circular	
plasmid	 DNA.2	 This	 complex	 serves	 as	 a	 standard	 for	 single	 strand	 breaks	 to	 the	
pUC19	DNA	and	 is	 included	on	all	 gels.	Alternatively,	 complexes	 that	 form	double	
strand	 breaks	 are	 highly	 desirable.	 This	 effect	 is	 included	 as	 a	 standard	 on	 gels	
through	 the	 use	 of	 the	 restriction	 enzyme	 EcoRI.3	 Severe	 damage	 to	 the	 DNA	
through	 double	 strand	 breaks	 produces	 linear	 DNA	 leading	 to	 cell	 death.	 Double	
strand	 breaks	 require	 homologous	 recombination	 or	 nonhomologous	 end‐joining	
repair	mechanisms.	This	type	of	damage	is	most	severe	because	neither	strand	can	
serve	as	a	template	for	repair,	resulting	in	cell	death	upon	the	subsequent	cell	cycle.4	
Complexes	that	display	this	ability	should	be	addressed	in	future	work.	 	
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40	μg/mL	pUC19	DNA	was	dosed	with	increasing	amounts	of	each	ruthenium	
complex	 followed	 by	 irradiation	 with	 blue	 light	 for	 one	 or	 three	 hours.	 Initial	
samples	were	pulled	before	light	activation,	and	were	protected	from	light	to	serve	
as	the	dark	control.	Due	to	the	numerous	compounds	synthesized,	this	chapter	will	
be	 divided	 into	 the	 following	 parts:	 1)	 by	 active	 species	 a)	 (Ru(bpy)2	 and	 b)	
Ru(dmphen)2,	2)	complexes	that	 intercalate,	and	3)	complexes	that	produce	single	
strand	DNA	breaks.	A	comprehensive	table	is	provided	at	the	end	of	the	chapter	that	
summarizes	the	type	of	damage	and	IC50’s	observed	at	three	hours	(Table	4.1).	The	
digital	 images	of	agarose	gels	 for	the	dark	control,	one	and	three	hour	time	points	
are	 included	 in	Figure	4.6.	 This	 figure	 contains	 all	 gels	 produced	by	 complexes	 in	
this	 thesis.	 These	 gels	 provide	 information	 on	 the	 types	 of	 DNA	 damage	 the	
complexes	 create	 and	 the	 concentration	 of	 the	 compound	 required	 to	 achieve	 the	
effect.	 Combining	 this	mechanistic	 information	with	 the	 cell	 viability	 can	 provide	
insight	 into	the	 in	vivo	results	shown	in	the	A549	cell	viability	assays	(see	Chapter	
5.1).	
1a)	Complexes	that	form	the	Ru(bpy)2	backbone	upon	light	activation	
Complexes	producing	similar	active	species	(for	example,	Ru(bpy)2,	see	Table	
3.2,	ESI‐MS	Data)	are	highlighted	in	Figure	4.2.	Complexes	GL002,	003,	006,	007,	and	
014	produce	the	same	Ru(bpy)2	active	species	and	display	cross‐linking	ability	with	
pUC19	DNA	with	IC50	values	of	15,	30,	30,	30,	and	15	μM,	respectively	on	the	three	
hour	gel.		
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Figure	4.2:	Complexes	with	Ru(bpy)2	active	species		
GL002		 	 	 	 	 GL003	
	 	 	
GL006		 	 	 	 	 GL007	
	 	
GL014	
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The	one	and	three	hour	gels	for	GL002	are	similar	due	to	the	kinetic	ability	of	
the	complex	to	readily	produce	the	active	species	(t1/2	=	1.9	minutes,	see	Table	3.1),	
which	 is	capable	of	photo‐binding	DNA.	GL003,	006,	and	007	show	similar	effects,	
but	with	less	potency	to	the	pUC19	DNA	with	IC50	values	of	30	μM.	Since	the	same	
species	are	generated,	 it	 is	 surprising	 that	 the	 IC50	values	are	not	equivalent.	This	
disconnect	 is	 explained	 by	 the	 fact	 that	 GL003,	 006,	 007,	 and	 014	 are	 kinetically	
slower	 to	 produce	 the	 active	 species	 with	 t1/2	 values	 of	 62,	 >	 232,	 128,	 and	 60	
minutes	respectively	(see	Table	3.1).	This	decreased	efficiency	to	produce	the	active	
species	 results	 in	 the	 differences	 observed	 in	 the	 one	 and	 three	 hour	 time	 points	
associated	with	the	complexes’	gels.	The	slow	ejection	 is	correlated	with	the	more	
planar	ligands	used	in	the	complex	(see	Table	2.2).	The	slight	smearing	of	GL003	at	
the	3	hours	time	point	is	indicative	of	the	intercalating	ability	of	the	dmdpq	ligand	
into	 the	 base	 stack	 of	 the	 DNA	 and	 the	 subsequent	 unwinding	 of	 the	 DNA.5		
Smearing	 due	 to	 intercalation	 is	 also	 observed	 in	 its’	 non‐photoejecting	 analogue,	
GL021.	This	complex	is	an	efficient	single	strand	DNA	breaker	and	has	an	IC50	of	30	
μM.	The	gels	for	GL003	and	007	display	both	cross‐linking	and	single	strand	breaks	
at	three	hours	with	the	pUC19	DNA.	It	displays	the	anticipated	single	strand	breaks	
associated	 with	 other	 ruthenium‐phenanthroline	 complexes.	 This	 is	 attributed	 to	
the	 generation	 of	 reactive	 oxygen	 species	 (ROS,	 see	 section	 3,	 complexes	 that	
produce	 single	 strand	DNA	breaks	with	 pUC19	DNA).	 Complex	GL014	 also	 shows	
similar	 cross‐linking	 to	GL002	 in	 addition	 to	 single	 strand	breaks	observed	 in	 the	
three	hour	gel.	The	ability	 to	bind	DNA	and	produce	single	strand	breaks	with	the	
addition	 of	 the	 bathophen	 ligand	might	 account	 for	 the	 increased	 dark	 A549	 cell	
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viability	 that	 is	 observed	 (dark	 IC50	 value	 =	 9.3	 μM,	 see	 Table	 5.5).	 Complexes	
containing	the	bis‐bathophen	backbones	should	be	synthesized	to	increase	potency.	
The	 issue	 with	 increased	 dark	 toxicity	 could	 possibly	 be	 relegated	 through	 the	
addition	of	negatively	charged	ligands.		
1b)	Complexes	that	produce	the	Ru(dmphen)2	backbone	
Other	complexes	containing	similar	backbones	are	highlighted	in	Figure	4.5.	
Complexes	 GL018,	 019,	 022,	 023,	 and	 039	 contain	 the	 Ru(dmphen)2	 backbone.	 A		
~50	nm	red	shift	 in	 the	absorbance	 is	gained	through	the	addition	of	 the	dmphen	
backbone	(see	Figure	3.2).		
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Figure	4.3:	Complexes	containing	the	Ru(dmphen)2	backbone	
GL018		 	 	 	 	 GL019	
	 	
GL022		 	 	 	 	 GL023	
	 	
GL039	
	
	
Complexes	 GL018	 and	 019	 are	 quinoline‐containing	 complexes	 that	 cross‐
link	pUC19	DNA	with	 IC50	 values	of	30	μM	at	 three	hours.	GL019	produces	 single	
strand	 breaks	 in	 addition	 to	 cross‐links.	 Quinoline	 ligands	 are	 known	 to	 have	
cytotoxic	capabilities	and	are	discussed	 in	Chapter	2.1.6	Both	complexes	display	 in	
vitro	IC50	values	of	30		μM		and	considerable	toxicity	to	A549	cells	with	IC50	values	of	
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0.3	and	0.6	μM	respectively	(see	Table	5.5).	Complexes	GL022	and	023	are	equally	
efficient	at	cross‐linking	pUC19	DNA	with	IC50	values	of	15	μM	and	are	considerably	
potent	 on	 A549	 cells	 with	 IC50	 values	 of	 1.2	 μM	 and	 0.2	 μM	 (see	 Table	 5.5)	
respectively.	The	DNA	binding/intercalation	observed	in	complex	GL023	is	thought	
to	stem	from	the	addition	of	the	bp	ligand	(see	Table	2.2).	GL039	efficiently	cross‐
links	pUC19	DNA	as	well,	with	an	IC50	value	of	15	μM	at	three	hours.	In	addition	to	
cross‐links,	 the	 complex	 also	produces	 single	 strand	breaks	 and	 intercalates	DNA.	
The	increased	DNA	affinity	stems	from	the	addition	of	the	planar	dpq	ligand	to	the	
Ru(dmphen)2	 backbone	 and	 produces	 similar	 intercalating	 results	 observed	 in	
similar	complexes	GL003,	009,	and	010.	The	increased	DNA	affinity	 is	observed	 in	
the	A549	cell	viability	experiment	with	a	dark	IC50	result	of	49.4	μM	(see	Table	5.5).		
2)	Complexes	that	intercalate	pUC19	DNA	
	 Complexes	GL009	and	010	were	synthesized	with	the	purpose	of	generating	
compounds	that	strongly	interact	with	the	DNA	duplex	through	intercalation.	These	
compounds	contain	the	dppz	ligand	(see	Table	2.1),	which	is	a	large	planar	system	
that	allows	for	intercalation	through	pi	stacking	with	the	bases	of	DNA.	DNA	binding	
affinity	 values	 of	 108	 M‐1	 have	 been	 reported	 in	 the	 literature	 for	 similar	 dppz	
containing	complexes.7	The	effects	of	GL009	and	010	are	shown	in	Figure	4.4.	
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Figure	4.4:	pUC19	Intercalating	ruthenium	complexes	
GL009		 	 	 	 	 GL010	
	
	
	 	These	 compounds	display	 similar	 results	 to	GL003,	where	 smearing	of	 the	
DNA	plasmid	was	observed	in	the	gels.	While	GL009	shows	no	cross‐linking	because	
it	 is	 not	 photoative,	 GL010	 can	 slowly	 produce	 the	 same	 Ru(bpy)2	 active	 species	
((t1/2	=	 >	 6	 hrs),	 see	 Table	 3.1)	 resulting	 in	 the	 observed,	 although	 slight	 cross‐
linking	 at	 the	 three	 hour	 time	 point.	 This	 is	 consistent	 with	 the	 narrow	 in	 vivo	
phototherapeutic	window	of	2.1	for	GL010	(see	Table	5.5).		
3)	Complexes	that	produce	single	strand	DNA	breaks	with	pUC19	DNA	
Ruthenium	complexes	can	generate	 singlet	oxygen,	producing	single	 strand	
breaks	in	DNA.	This	type	of	damage	from	the	evolution	of	singlet	oxygen	is	known	in	
the	literature.8	Complexes	GL004,	005,	011	and	021	display	single	strand	breaks	and	
are	highlighted	in	Figure	4.5.	
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Figure	4.5:	Ruthenium	Complexes	Producing	Single	Strand	Breaks	in	pUC19	DNA	
GL004		 	 	 	 	 GL005	
	 	
GL021		 	 	 	 	 GL011	
	 	
	
GL004,	 011,	 and	021	have	 similar	planar	 co‐ligands	 (phen	 and	dpq)	 as	 the	
Cu(phen)2	standard	and	yield	similar	single	strand	breaks	with	IC50	values	of	15	and	
30	μM	respectively.	Complex	GL005	was	synthesized	to	create	an	active	species	that	
was	negatively	charged	to	assess	the	importance	of	charge	state	in	interacting	with	
the	 DNA.	 The	 IC50	 value	 for	 complex	 GL005	 is	 approximately	 60	 μM	 at	 the	 three	
hour	time	point	(note	that	only	about	10%	of	the	pUC19	DNA	is	converted	to	single	
strand).	Producing	 the	 active	 species	 of	GL005	 is	 kinetically,	 very	 efficient,	with	 a	
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t1/2	 of	 0.6	 minutes	 (see	 Table	 3.1).	 The	 complex	 contains	 the	 bis‐
bathophendisulfonate	backbone	to	give	an	overall	charge	of	 ‐2,	while	a	majority	of	
the	 complexes	 discussed	 in	 this	 work	 have	 an	 overall	 charge	 of	 +2.	 The	 yield	 of	
ssDNA	produced	by	GL005	is	low	compared	to	GL004.	This	is	thought	to	be	due	to	
the	 photoejection,	 which	 decreases	 the	 yield	 of	 1O2.	 There	 is	 also	 a	 decreased	
electrostatic	 interaction	 with	 the	 DNA	 through	 the	 addition	 of	 the	 negatively	
charged	backbone.	This	would	suggest	that	GL005	would	have	very	low	potency	in	
cell	studies,	but	a	150‐fold	window	is	observed	in	the	A549	cell	viability	assay	(see	
Table	5.5).	Limited	dark	toxicity	(200	μM)	is	also	observed	in	A549	cells	supporting	
the	 decreased	 affinity	 through	 the	 negatively	 charged	 backbone.	 Additional	
complexes	with	similar	backbones	should	be	synthesized	to	prove	this	hypothesis.		
Complex	GL011	shows	efficient	cross‐linking	at	an	IC50	value	of	30	μM	with	
single	 strand	 breaks	 occurring	 at	 higher	 concentrations.	 The	Ru(phen)2	 backbone	
with	the	addition	of	a	biquinoline	ligand	shifts	the	absorbance	to	the	red	by	~60	nm	
(see	Figure	3.2).	A	phototherapeutic	ratio	of	5.4	(see	Table	5.5)	 is	observed	 in	 the	
A549	 cell	 viability	 assay.	 Similar	 derivatives	will	 be	 important	 in	 future	 research	
due	 to	 the	 deeper	 tissue	 penetrating	 nature	 associated	 with	 red	 shifted	
absorbances.9	The	IC50’s	and	type	of	damage	observed	at	three	hours	is	summarized	
in	Table	4.1.	
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Table	4.1:	Summary	of	IC50	Values	and	Types	of	Damage	Observed	at	Three	Hours	
Complex	Code	 IC50	(μM)	 Type	of	Damage	
Observed	
Cisplatin	 31	 Cross‐link	
GL002	 15	 Cross‐link/S.S	Breaks	
GL003	 31	 Cross‐link/S.S	
Breaks/Intercalate	
GL004	 15	 S.S.	Breaks	
GL005	 31	 S.S.	Breaks	
GL006	 31	 Cross‐link/S.S	Breaks	
GL007	 31	 Cross‐link/S.S	Breaks	
GL008	 62	 Cross‐link/S.S.	Breaks	
GL009	 <7.5	 Intercalate	
GL010	 >62	 Intercalate/Cross‐link	
GL011	 31	 Cross‐link/S.S	Breaks	
GL013	 No	Effect	Observed	 No	Effect	Observed	
GL014	 15	 Cross‐link/S.S	Breaks	
GL018	 31	 Cross‐link	
GL019	 31	 Cross‐link/S.S	Breaks	
GL021	 31	 Intercalate/S.S.	Breaks	
GL022	 15	 Cross‐link/S.S.	Breaks	
GL023	 15	 Cross‐link/Intercalate/S.S.	
Breaks	
GL039	 15	 Cross‐link/Intercalate/S.S.	
Breaks	
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Figure	4.6:	Ruthenium	Complexes	with	pUC19	DNA	
Cisplatin	
	 	
	
GL002		 	 	 	 	 GL003	
	 	
GL004		 	 	 	 	 GL005		 	 	 	
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Figure	4.6:	Ruthenium	Complexes	with	pUC19	DNA	(cont.)	
Gl006	 	 	 	 	 	 GL007	
	 	
GL008		 	 	 	 	 GL009	
	 	
GL010		 	 	 	 	 GL011	
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Figure	4.6:	Ruthenium	Complexes	with	pUC19	DNA	(cont.)	
GL013		 	 	 	 	 GL014	
	 	
GL018		 	 	 	 	 GL019	
	
	
GL021		 	 	 	 	 GL022	
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Figure	4.6:	Ruthenium	Complexes	with	pUC19	DNA	(cont.)	
GL023		 	 	 	 	 GL039	
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4.2.	 Reaction	 of	 GL002	 with	 Calf	 Thymus	 DNA	 Monitored	 by	 UV‐Vis	
Spectroscopy	
To	determine	the	binding	kinetics	for	the	reaction	of	the	activated	ruthenium	
complex	with	DNA,	20	μM	GL002	was	reacted	with	100	μM	(base	pairs)	calf	thymus	
(CT)	DNA	in	10	mM	NaH2PO4	buffer	at	37	oC.	Control	dark	reactions	with	GL002	and	
CT	DNA	yielded	very	 little	 change	 in	 the	 spectra	 over	24	hours	 and	 are	 shown	 in	
Figure	 4.7a.	 Figure	 4.7b	 displays	 the	 reaction	 of	 photo‐activated	 GL002	 upon	 the	
addition	of	CT	DNA,	where	scans	were	taken	over	a	period	of	seven	hours	to	provide	
the	kinetic	profile	 for	 the	reaction.	The	CT	DNA	reacts	rapidly,	as	observed	by	 the	
spectral	change	observed	in	Figure	4.7b.	A	decrease	in	absorbance	around	400	nm	
with	an	increase	absorbance	around	490	nm	is	observed.	To	determine	the	reaction	
rate,	 data	 was	 collected	 in	 triplicate	 and	 the	 change	 in	 absorbance	 was	 plotted	
against	time	to	create	a	time	course	for	the	reaction.	The	data	was	fit	to	an	equation	
for	a	‘one	phase	association’	using	Prism	software	and	is	shown	in	Figure	4.7c.	The	
calculated	half‐life	for	the	reaction	is	52	minutes.	 	The	selectivity	of	GL002	to	only	
bind	the	DNA	after	light‐activation	serves	as	a	prodrug	model	for	PDT	use.	
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Figure	4.7:	Kinetic	profile	of	GL002	with	100	μM	Calf	Thymus	DNA:	a)	Dark	reaction,	
b)	Light	activated	002	with	CT	DNA,	c)	Light	activated	kinetics			
4.3	Reaction	of	GL002	with	Guanosine	Monitored	by	UV‐Vis	spectroscopy	
	 Although	cisplatin	 is	 capable	of	binding	guanine,	 cytosine,	and	adenine,	 the	
preferred	 base	 is	 guanine.10	 Cisplatin	 binds	 at	 the	 N7	 position	 of	 the	 base	 and	 is	
capable	of	forming	interstrand	and	intrastrand	cross‐links.11	Intrastrand	cross‐links	
between	the	N7	atoms	of	adjacent	guanine	residues	produce	distortion	of	the	DNA	
backbone.1,	12,12a	
Once	 the	binding	kinetics	 for	 the	 reaction	of	GL002	with	Calf	Thymus	DNA	
were	determined	(see	Figure	4.7)	and	preference	to	guanosine	was	found	through	
nucleoside	selectivity	experiments	using	LC‐MS	(see	Figure	3.3),	the	binding	kinetics	
for	 GL002	 with	 guanosine	 was	 determined	 using	 UV‐Vis	 spectroscopy.	 This	 was	
assessed	by	reacting	20	μM	GL002	with	1	mM	Guanosine	in	10	mM	NaH2PO4	buffer	
at	37	oC.		To	ensure	that	the	interaction	of	guanosine	was	mediated	by	the	activated	
GL002,	 control	 dark	 experiments	 were	 performed	 with	 unactivated	 GL002.	 The	
results	 from	 this	 control	 showed	 that	 GL002	 does	 not	 react	 significantly	 with	
guanosine	over	several	hours.	When	GL002	was	photo‐activated,	it	reacted	quickly	
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with	 guanosine	 as	 observed	 by	 the	 spectral	 change	 in	 Figure	 4.8b.	 Data	 was	
collected	 for	 two	hours	 following	 the	 addition	 of	 activated	GL002	with	 guanosine	
and	the	kinetics	for	the	reaction	were	measured	and	plotted	using	the	difference	in	
absorbance	at	495	and	410	nm.	The	curve	was	fit	with	‘one	phase	association’	with	`	
Prism	software.	The	calculated	half‐life	of	the	reaction	is	12.7	minutes.			
Figure	4.8:	Kinetic	Profile	of	GL002	with	1	mM	Guanosine:	a)	Dark	reaction,	b)	Light	
activated	002	with	guanosine,	c)	Light	activated	kinetics		
	
4.4.		Reaction	of	GL002	with	Glutathione	Monitored	by	UV‐Vis	Spectroscopy	
	 Glutathione	(GSH)	is	a	sulfur	containing	tripeptide	that	is	highly	reactive	and	
found	in	most	cells.	Present	in	cells	at	concentrations	ranging	from	1‐30	mM,13	GSH	
plays	several	roles	including	antioxidation	and	maintenance	of	the	redox	state.	One	
of	 the	most	 important	role	of	GSH	 is	detoxification	of	carcinogens,13a	and	elevated	
levels	 of	 GSH	 lead	 to	 chemotherapeutic	 drug	 resistance	 and	 aid	 in	 cell	 survival.14	
GSH	 is	problematic	 to	cisplatin	as	 the	soft	 thiol	groups	have	a	high	affinity	 for	 the	
soft	platinum(II)	metal.	Pearson’s	values	of	hardness	(η)	 for	platinum2+	and	sulfur	
are	8.0	and	4.14,	respectively.15		The	large	difference	ensures	good	covalent	overlap	
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between	 the	 Pt2+	 and	 S	 atoms.	 Cisplatin/GSH	 kinetics	 are	 known	 in	 the	 literature	
and	are	relatively	fast	at	a	t1/2	=	~53	minutes.13c	To	determine	the	binding	kinetics	
of	GL002,	16	mM	GSH	was	reacted	with	20	μM	GL002	in	NaH2PO4	buffer.	Addition	of	
GSH	to	inactivated	GL002	yielded	no	activity	over	48	hours	(Figure	4.9a).	The	ability	
to	evade	detoxification	agents	like	GSH	while	inactive	may	allow	for	effective	dosing	
of	PDT	patients	with	the	prodrug	GL002.	Addition	of	GSH	to	photo‐activated	GL002	
yielded	a	slow	reaction,	with	a	t1/2	=	247.6	minutes.	The	Pearson’s	value	of	hardness	
for	Ru2+	is	slightly	lower	than	that	of	Pt2+	at	5.86.15		However,	this	is	an	estimate	for	
the	 metal	 only	 and	 not	 for	 a	 coordination	 complex	 with	 aromatic	 ligands,	 which	
affect	the	electron	density	of	the	metal	center.	This	experimental	results	show	that	
sulfur	 has	 a	 higher	 affinity	 for	 the	 platinum	 in	 cisplatin	 over	 ruthenium	 in	
polypyridyl	 complexes.	 This	 is	 consistent	with	 some	 results	 in	 the	 literature	 that	
shows	some	ruthenium	complexes	prefer	nitrogen	to	sulfur.16	
Figure	4.9:	Kinetic	Profile	of	GL002	with	GSH:	a)	Dark	 reaction,	b)	Light	activated	
002	with	GSH,	c)	Light	activated	kinetics	
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Chapter	4:	In	Vitro	Experimental	
In	Vitro:	Agarose	Gel	Electrophoresis	Experimental	
Materials:		
The	pUC19	plasmid	DNA	was	obtained	from	ATCC	and	was	purified	with	the	
Maxi	 Prep	 kit	 by	 Qiagen.	 Buffered	 solutions	 containing,	 tris	 base,	 and	 acetic	 acid	
were	 obtained	 from	Sigma,	 VWR	or	 Fisher	 and	were	 prepared	 to	 the	 appropriate	
concentrations	using	Glazer	Lab	Agarose	Gel	Electrophoresis	Protocols.	Ingredients	
for	 the	 DNA	 loading	 dye	 include	 bromophenol	 blue,	 xylene	 cyanol,	 and	 glyceron	
were	obtained	from	VWR	and	prepared	to	appropriate	concentrations	using	Glazer	
Laboratory	 Protocols.	 Single	 strand	 breaks	 of	 the	 plasmid	 (relaxed	 circle)	 were	
observed	 using	 copper	 phenanthroline	 (Cu(phen)2)	 obtained	 from	 Sigma	 and	
prepared	 via	 the	 reaction	 outlined	 below.	Reagent	 grade	 dithiothreitol	 (DTT)	 and	
H2O2	were	 obtained	 from	VWR.	 Double	 strand	 (linear	 DNA)	 breaks	 to	 the	 pUC19	
plasma	DNA	were	observed	using	 the	endonuclease	enzyme	EcoR1	obtained	 from	
Fisher	and	was	prepared	per	protocol	outlined	below.	A	DNA	ladder	from	Promega	
was	 used	 for	 mass	 estimation	 of	 DNA	 fragments	 produced	 and	 was	 prepared	
through	the	procedure	outlined	below.	Pure	agarose	was	obtained	from	Fisher	and	
prepared	using	the	protocol	outlined	below.	Gel	rigs	used	for	running	the	gels	were	
also	obtained	from	BioRad.	Gels	were	stained	with	ethidium	bromide	(Fisher)	and	
digitally	imaged.		
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Single	Strand	DNA	Break	Cu(OP)2	Reaction:	
Single	 strand	 breaks	 of	 the	 pUC19	 plasmid	DNA	were	 created	 through	 the	
incubation	of	40	μg/mL	of	pUC19	in	10	mM	phosphate	buffer,	pH	7.4	mixed	with	8	
μM	Cu(phen)2.	The	reaction	was	initiated	with	the	addition	of	4	μL	of	5	mM	DTT	and	
4	μL	of	5	mM	H2O2.	The	reaction	mixture	was	vortexed	for	10	seconds	and	allowed	
to	incubate	at	room	temperature	for	30	minutes.	Prior	to	loading	onto	the	agarose	
gel,	6	μL	of	DNA	loading	dye	was	added	to	the	sample.			
Double	Strand	DNA	break	EcoR1	Reaction:	
	 Double	strand	breaks	of	the	pUC19	plasmid	DNA	were	accomplished	through	
the	incubation	of	40	μg/mL	of	pUC19	with	8	μL	of	EcoR1,	a	DNA	restriction	enzyme,	
mixed	with	10	μL	10X	EcoR1	buffer.		The	appropriate	amount	of	dH2O	was	added	to	
bring	the	final	volume	to	100	μL.	The	solutions	were	thoroughly	mixed	and	allowed	
to	react	at	37	oC	for	90	minutes	on	a	heat	block.	Upon	completion	and	prior	to	use,	
20	μL	of	6X	DNA	loading	dye	was	added.	
DNA	Ladder	for	Mass	Estimation	of	DNA	Fragments:	
	 Mass	estimation	of	 the	DNA	fragments	produced	was	observed	through	the	
use	of	a	1Kbase	pair	ladder.	10	μL	of	the	1Kbase	pair	ladder	was	diluted	10X	with	20	
μL	of	6X	loading	dye	and	dH2O.		
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Agarose	Gel	Preparation:	
	 1%	agarose	gels	were	prepared	by	mixing	0.5	g	agarose	with	50	mL	of	1X	tris	
acetate	 buffer	 and	 heated	 to	 boiling	 ensure	 complete	 dissolution	 in	 a	microwave.		
The	 solution	was	 then	poured	 into	 the	gel	deck	with	a	15	well	 comb	 in	place	and	
allowed	to	solidify	for	at	least	30	minutes.	Once	solidified,	the	gel	was	placed	in	the	
gel	rig	filled	with	1X	tris	acetate	running	buffer.		
Sample	Preparation:	DNA	dosing	and	Light	Activation	
A	 dilution	 series	 was	 prepared	 in	 clear,	 96‐well	 flat	 bottom	 plates	 (clear,	
Costar)	of	the	following	ruthenium	complex	concentrations	in	10	mM	Na2PO4	buffer:	
500	 μM,	 250	 μΜ,	 125	 μM,	 62.5	 μM,	 31.3	 μM,	 15.6	 μM,	 7.8	 μM,	 and	 0μM.	 pUC19	
plasmid	DNA	concentration	was	added	 to	each	well	at	40	μg/mL	(final	volume	90	
μL).	A	30	μL	aliquot	was	removed	for	each	dose	point	to	serve	as	the	dark	control.	
The	remaining	60	μL	were	exposed	to	blue	light	from	a	200	W	Dell	projector.	30	μL	
sample	aliquots	were	removed	at	1	hour	and	3	hours	of	light	activation.		After	light	
exposure	the	samples	were	allowed	to	react	at	room	temperature	overnight.	Prior	
to	loading	on	the	agarose	gel	6	μL	of	6X	DNA	loading	dye	were	added	to	each	30	μL	
sample	 aliquots	 with	 8	 μL	 of	 the	 samples	 being	 loaded	 into	 the	 gel	 well.	 Typical	
order	 of	 the	 loaded	 samples	 is:	 DNA	 ladder,	 EcoR1,	 Cu(OP)2,	 0	 μM	 ruthenium	
complex	 to	 500	 μM	 ruthenium	 complex,	 DNA	 ladder.	 The	 gels	 were	 run	 for	 75	
minutes	at	100	mV.	Gels	were	stained	with	7.5	μL	of	ethidium	bromide	in	150	mL	1X	
Tris	acetate	Buffer	 for	40	minutes	 followed	by	de‐staining	of	 the	gels	with	a	 fresh	
150	mL	aliquot	of	1X	tris	acetate	buffer	for	30	minutes	and	imaged	digitally.		
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4.2	In	Vitro:	GL002	with	Calf	Thymus	DNA	by	UV‐Vis	spectroscopy:	Experimental	
Reaction	 kinetics	 were	 obtained	 for	 GL002	 with	 Calf	 Thymus	 DNA	 in	
NaH2PO4	buffer	at	pH	7.4	at	37	oC	using	an	Agilent	8353	UV‐Vis	spectrophotometer	
equipped	with	Chemstation	B.02.01	 software	and	a	 temperature	 controller	peltier	
(Agilent	89090A).		Calf	thymus	DNA	was	obtained	from	ATCC	and	sonicated	for	30	
minutes	to	produce	uniform	breaks	in	the	DNA.		The	instrument	was	blanked	on	7	
μL	 of	 1M	NaH2PO4	 at	 pH	 7.4	 (10	mM)	 and	 691	 μL	 of	 deionized	water	 in	 a	 small	
volume	cuvette.	2.1	μL	of	GL002	(6.55	mM)	was	added	to	the	blank	solution	to	give	
002:	 NaH2PO4	 concentrations	 of	 20	 μM:	 10	mM	 respectively.	 Following	 an	 initial	
scan,	the	cuvette	was	placed	under	the	Dell	projector	(see	Chapter	3.1)	and	exposed	
to	 blue	 light	 until	 no	 change	 was	 observed	 in	 the	 UV	 spectra	 confirming	 the	
complete	 conversion	 of	 the	 complex	 to	 the	 Ru(bpy)2	 active	 species..	 The	 reaction	
was	initiated	through	the	addition	of	5.8	μL	sonicated	calf	thymus	DNA	(5160	μM	in	
base	 pairs)	 to	 294.2	 μL	 of	 the	 compound/buffer	 solution	 above	 to	 give	 the	 final	
002:CT	DNA:	NaH2PO4	concentrations	of	19.6	μM:	100	μM:	9.8	mM	respectively.	The	
cuvette	was	placed	in	the	sample	holder	with	the	peltier	temperature	controller	set	
to	 37	 oC.	 Scans	 were	 taken	 periodically	 until	 no	 spectral	 change	 was	 observed.	
Triplicate	 measurements	 were	 obtained	 and	 curves	 were	 fit	 using	 one	 phase	
association	in	Prism	software.	
4.3	In	vitro;	GL002	with	Guanosine	by	Uv‐Vis	spectroscopy:	Experimental	
The	 reaction	kinetics	were	obtained	 for	GL002	with	guanosine	 (Alfa	Aesar,	
CAS	118‐00‐3)	 in	NaH2PO4	 (Sigma)	buffer	 at	 pH	7.4	 at	 37	 oC	using	 the	previously	
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mentioned	UV‐Vis	Spectrophotometer.	The	instrument	was	blanked	on	3	μL	of	1	M	
NaH2PO4	(10	mM)	and	296.1	μL	of	deionized	water	in	a	small	volume	cuvette.	0.92	
μL	 of	 6.55	mM	GL002	 (20	 μM)	was	 added	 to	 the	 cuvette	 and	 an	 initial	 scan	was	
taken.	The	sample	was	place	under	the	Dell	projector	(see	Chapter	3.1)	under	blue	
light	until	no	spectral	change	was	observed	and	photoejection	was	complete.	9	μL	of	
a	33.5	mM	guanosine	stock	 in	DMSO	was	added	 to	291	μL	of	 the	GL002/NaH2PO4	
buffered	solution	to	give	GL002:	guanosine:	NaH2PO4	concentrations	of	19.4	μM:	1	
mM:	 9.7	 μM	 respectively.	 The	 cuvette	 was	 placed	 in	 the	 sample	 holder	 with	 the	
peltier	 set	 to	 37	 oC.	 Scans	 were	 taken	 periodically	 until	 no	 spectral	 change	 was	
observed.	Triplicate	measurements	were	obtained	and	the	resulting	curves	were	fit	
using	one	phase	association	in	Prism	software.		
4.4	In	Vitro:	GL002	with	Glutathione	
The	 reaction	 kinetics	 were	 obtained	 for	 GL002	 and	 L‐glutathione	 reduced	
(GSH,	Sigma,	CAS	70‐18‐8)	 in	NaH2PO4	(Sigma)	buffer	at	pH	7.4	at	37	oC	using	the	
previously	mentioned	UV‐Vis	spectrophotometer.	The	instrument	was	blanked	on	3	
μL	of	1	M	NaH2PO4	(10	mM)	and	2498.13	μL	of	deionized	water	in	a	3	mL	cuvette.		
0.92	μL	of	65.5	mM	GL002	(20	μM)	was	added	to	the	cuvette	and	an	initial	scan	was	
taken.	The	sample	was	place	under	the	Dell	projector	(see	Chapter	3.1)	under	blue	
light	until	no	spectral	change	was	observed	and	photoejection	was	complete.	480	μL	
of	100	mM	GSH	(16	mM)	was	added	to	the	mixture	and	the	cuvette	was	place	in	the	
sample	holder	with	the	peltier	set	 to	37	oC.	Scans	were	taken	periodically	until	no	
91	
	
spectral	 change	 was	 observed.	 Triplicate	 measurements	 were	 obtained	 and	 the	
resulting	curves	were	fit	using	the	one	phase	association	in	Prism	software.		
Chapter	5:	In	Vivo	Studies	of	Light‐Activated	Ruthenium	Complexes	
Dr.	David	Heidary	contributed	to	this	chapter.	
Introduction	
In	 vitro	 results	 indicate	 that	 the	 synthesized	 ruthenium	 complexes	 are	
capable	 of	 cross‐linking	 DNA	 when	 photo‐activated.	 In	 order	 to	 test	 their	 in	vivo	
activity,	 experiments	 were	 carried	 out	 on	 the	 A549	 cell	 line.	 A549	 or	
adenocarcinomic	 human	 alveolar	 basal	 epithelial	 cells	 are	 a	 non‐small	 cell	 lung	
cancer	cell	line.	These	adherent	cells	are	responsible	for	the	diffusion	of	water	and	
electrolytes	 across	 the	 alveoli	 of	 lungs	 and	 are	 cultured	 as	 a	 monolayer.	 	 The	
immortalized	 cell	 line	 was	 derived	 from	 an	 explanted	 tumor	 of	 a	 58‐year‐old	
Caucasian	 male.17	 The	 lung	 cancer	 cell	 line	 was	 chosen	 as	 a	 good	 model	 for	
photodynamic	 therapy	 as	 the	 lung	 is	 easily	 accessible	 with	 a	 light	 source	 and	
photodynamic	therapy	has	been	applied	with	success	to	lung	cancer.	18		
Chapter	5.1:	A549	Cytotoxicity	Assays	
Successful	photodynamic	 therapy	hinges	on	 the	ability	 to	provide	cytotoxic	
results	only	when	 the	 complexes	are	activated	with	 light.	As	described	 in	Chapter	
2.2,	multiple	complexes	have	been	synthesized	to	examine	cell	cytotoxicity	in	search	
of	 a	 good	 balance	 of	 light	 and	 dark	 toxicity.	 Due	 to	 the	 numerous	 compounds	
synthesized,	 this	 chapter	 will	 be	 divided	 and	 discussed	 as	 follows:	 1)	 by	 active	
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species	 a)	 (Ru(bpy)2	 and	b)	Ru(dmphen)2	 and	how	 the	 in	vivo	 A549	assay	 results	
relate	 to	structural	design	(see	Chapter	2	Design)	and	photo‐ejection	kinetics	 (see	
Chapters	 3);	 2)	 in	 vitro	 pUC19	 DNA	 results	 (see	 Chapter	 4.1),	 with	 regards	 to	
complexes	 that	crosslink	DNA	or	produce	single	strand	DNA	breaks,	3)	complexes	
with	different	overall	charges,	and	4)	summary	and	future	work.	Complexes	that	fit	
the	criteria	for	each	feature	will	be	grouped	and	discussed.	Figures	that	correspond	
to	 relevant	 compounds	 discussed	will	 be	 included	 in	 the	 text	 and	 all	 cytotoxicity	
results	 will	 be	 summarized	 in	 a	 comprehensive	 table	 included	 at	 the	 end	 of	 the	
Chapter.	For	all	experiments,	cisplatin	was	used	as	a	non‐light	activated	control;	 it	
displays	 a	 cytotoxic	 ratio	 of	 one	 as	 it	 displays	 no	 noticeable	 difference	 in	 the	
presence	of	light.	
Figure	5.1:	Cytoxicity	curve	of	cisplatin		
	
	 To	 test	 if	 only	 light	 activated	 complexes	 induced	 cytotoxicity,	 dark	 control	
experiments	were	 carried	 out	 to	 observe	 efficacy	 between	 the	 light	 activated	 and	
unactivated	 complexes.	 Cell	 viability	 was	 determined	 through	 an	 ATP	 luciferase	
assay	that	produces	luminescence	in	the	presence	of	ATP.		Detergent	lysis	was	used	
to	 rupture	 the	membrane	 gaining	 access	 to	 the	 cellular	 contents,	 and	 the	 enzyme	
luciferase	was	used	to	produce	luminescence	in	the	presence	of	ATP.	Populations	of	
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viable	 and	 dead	 cells	 are	 quantified	 through	 measuring	 luminescence	 with	 the	
Tecan	plate	reader.		
1a:	Complexes	that	produce	the	Ru(bpy)2	backbone		
Complexes	GL002,	003,	006,	007,	008,	010	have	similar	backbones	and	form	
the	same	Ru(bpy)2	active	species	following	activation	(Table	5.1).	
Table	5.1:	Complexes	that	produce	the	Ru(bpy)2	active	species	upon	light	activation			
Complex	
Code	
Name	
A549	Light	
(μM)	
A549	Dark	
(μM)	
A549	
phototherapeutic	
ratio	
GL002	 Ru(bpy)2dmbpy	 0.6	 250	 417	
GL003	 Ru(bpy)2dmdpq	 1.2	 250	 216	
GL006	 Ru(bpy)2	‐3,3’‐dmbpy	 30	 250	 8	
GL007	 Ru(bpy)2dmphen	 0.1	 8	 80	
GL008	 Ru(bpy)2bcds	 56.3	 64.5	 1.2	
GL010	 Ru(bpy)2dmdppz	 22	 47	 2.1	
GL014	 Ru(bpy)2bc	 2.4	 9.3	 3.9	
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Figure	5.2:	Example	curves	for	complexes	that	produce	the	Ru(bpy)2	active	species	
	 It	 is	 expected	 that	 complexes	 with	 similar	 backbones	 producing	 the	 same	
active	species	should	have	similar	light	IC50	values.	However,	with	these	complexes	
sharing	 the	 similar	 backbone,	 correlations	 between	 the	 structure	 and	 ejection	
profiles	 and	 the	 in	 vitro	 results	 can	 loosely	 be	 drawn	 to	 explain	 the	 potency	
observed	 in	 the	 in	vivo	 A549	 assay.	 The	 general	 trend	 is	 that	 complexes	 that	 are	
slower	to	produce	the	active	species	are	less	effective	at	cross‐linking	DNA	and	are	
less	potent	compared	to	their	faster	ejecting	derivatives.	The	model	complex	GL002	
shows	the	 largest	phototherapeutic	ratio	 for	 this	group	of	complexes	of	417.	Light	
activation	 of	 the	 compound	 resulted	 in	 an	 IC50	 of	 0.6	 μM	while	 the	 non‐activated	
compound	induced	cytotoxicity	with	an	IC50	of	250	μM.	A	similar	ratio	is	observed	
with	GL003	(216),	which	has	an	IC50	of	1.2	μM	and	dark	unactivated	IC50	of	250	μM.	
The	 slight	 decrease	 in	 light	 toxicity	 of	 GL003	 is	 attributed	 to	 the	 slower	 ejection	
profile	of	60.9	minutes	(see	Table	3.1).	This	compliments	the	two‐fold	increases	in	
the	complex’s	 IC50	 in	vitro	 result	 (see	Table	4.1).	Complex	GL007	 is	approximately	
50	times	slower	to	eject	than	GL002	(see	Table	3.1),	but	is	very	potent	against	the	
A549	cell	line	once	photo‐activated	(0.1	μM).	The	ejected	dmphen	ligand	(see	Table	
3.2)	appears	to	have	an	effect	on	the	cell	line,	increasing	the	dark	toxicity	similarly	
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to	what	is	observed	in	the	Ru(dmphen)2	activated	species	(see	Table	5.2).	This	may	
be	 attributed	 to	 the	 complexes’	 dual	 mechanism	 of	 cross‐linking	 and	 producing	
single	strand	breaks	as	seen	in	the	in	vitro	results	(Table	4.1).	Complexes	GL008	and	
014	are	structurally	similar	and	differ	only	by	overall	charge	through	the	addition	of	
the	sulfonate	groups	to	GL008	(see	Table	2.2).	The	negatively	charged	bcds	 ligand	
decreases	 the	 overall	 toxicity	 toward	 the	 cell	 line.	 This	 could	 be	 related	 to	 the	
electrostatic	 interaction	with	DNA,	 raising	both	 the	 light	 and	dark	 toxicity	 to	56.3	
and	64.5	μM	respectively.	This	compliments	the	in	vitro	results	as	well	(IC50	=	60	μM,	
see	 Table	 4.1),	 possibly	 indicating	 that	 the	 negatively	 charged	 ligand	 has	 a	
decreased	 affinity	 towards	 DNA.	 The	 addition	 of	 the	 bc	 ligand	 in	 complex	 GL014	
(see	Table	2.2)	has	the	opposite	effect,	decreasing	both	the	 light	and	dark	toxicity.	
This	complex	is	slow	to	eject	at	59.7	minutes	(see	Table	3.1),	but	fairly	potent	when	
light	 activated	 (2.4	 μM),	 and	 has	 considerably	 more	 dark	 toxicity	 resulting	 in	 a	
diminished	 phototherapeutic	 window	 of	 3.9.	 GL023	 incorporates	 a	 similar	 ligand	
and	has	considerable	dark	toxicity	(see	Table	5.2).	Diminished	potency	compared	to	
GL002	 after	 light	 activation	was	 observed	 for	 complexes	 GL006	 and	 GL010,	with	
IC50	values	of	30	and	22	μM	respectively,	despite	the	fact	that	they	produce	the	same	
active	species.	This	is	attributed	to	their	respective	slow	ejection	profiles	(t1/2	values	
of	 230	 and	 >6	 hrs	 respectively;	 see	 Table	 3.1).	 On	 average	 these	 complexes	 are	
approximately	150	times	slower	than	GL002	at	producing	the	active	species	capable	
of	cross‐linking	DNA.	As	shown	in	the	in	vitro	results,	GL006	has	an	IC50	of	30	μM	at	
3	hours	under	blue	 light;	 two	 fold	 less	effective	 that	GL002	at	 three	hours.	The	 in	
vitro	result	of	GL010	is	>	60	μM	at	3	hours,	a	difference	of	four	when	compared	to	
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GL002	(see	Table	4.1).	It	is	thought	that	the	dark	toxicity	stems	from	the	extended,	
planar	dmdppz	ligands	intercalating	nature	to	bind	DNA.	This	observation	is	evident	
in	the	three	hour	in	vitro	result	(see	Figure	4.1),	as	indicated	by	smearing	of	the	DNA.	
For	 complexes	GL006	and	010,	 irradiation	 times	 appear	 to	 be	 very	 important.	 To	
address	 the	 issue	 of	 complete	 conversion	 to	 the	 activated	 species,	 optimized	
irradiation	times	should	be	addressed	in	future	cell	assays	of	slow	ejectors	to	ensure	
complete	photo‐activation	of	the	complexes.	
1b:	Complexes	that	produce	the	Ru(dmphen)2	backbone		
A	 different	 approach	 was	 evaluated	 with	 complexes	 containing	 the	
Ru(dmphen)2	 backbone.	 Instead	 of	 the	 addition	 of	 one	 sterically	 hindered	 ligand	
added	to	the	Ru(bpy)2	backbone,	steric	clash	was	introduced	through	the		addition	
of	two	sterically	hindered	ligands	in	the	Ru(dmphen)2	backbone,	and	then	coupled	
with	various	unstrained	ligands.		Table	5.2	summarizes	the	complexes	that	produce	
the	Ru(dmphen)2	backbone	upon	light	activation.	
	
	
	
	
	
97	
	
Table	 5.2:	 Complexes	 that	 produce	 the	 Ru(dmphen)2	 active	 species	 upon	 light	
activation			
Complex	
Code	
Name	
A549	Light	
(μM)	
A549	Dark	
(μM)	
A549	
phototherapeutic	
ratio	
GL018	 Ru(dmphen)28HQ	 0.3	 0.3	 1	
GL019	 Ru(dmphen)22‐Me‐8HQ	 0.6	 1.2	 2	
GL022	 Ru(dmphen)2bpy	 1.2	 24.5	 20.4	
GL023	 Ru(dmphen)2bp	 0.2	 0.5	 2.5	
GL039	 Ru(dmphen)2dpq	 0.8	 49.4	 61.8	
	
Figure	 5.3:	 Cytoxicity	 curves	 of	 example	 complexes	 containing	 the	 Ru(dmphen)2	
backbone		
	 	
The	Ru(dmphen)2	backbone	provided	complexes	that	can	be	light	activated,	
but	 dark	 toxicity	 was	 sacrificed.	 These	 complexes	 have	 narrow	 phototherapeutic	
windows	 and	behave	 somewhat	 like	 traditional	 therapeutic	metal	 complexes.	 The	
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quinoline	 ligands	 alone	 are	 known	 cytotoxic	 agents	 and	 are	 discussed	 in	 Chapter	
2.1.19	GL018	and	019	were	synthesized	to	evaluate	the	phototherapeutic	ratio	of	the	
addition	 of	 these	 cytotoxic	 ligands	 with	 the	 strained	 backbone.	 On	 average,	 the	
ejection	 profiles	 of	 these	 complexes	 are	 13	 times	 slower	 than	 the	model	 complex	
GL002	(see	Table	3.1)	and	produce	different	photo‐ejection	products	(see	Table	3.2).	
GL018	produces	a	mixture	of	products	upon	light	activation	including	the	dmphen	
ligand	(similar	to	complex	GL007,	see	Table	3.2).	This	complex	is	potent	in	the	A549	
cell	line	with	an	IC50	=	0.3	μM	under	both	dark	and	light	conditions,	behaving	like	a	
traditional	chemotherapeutic	with	no	phototherapeutic	window.	The	photo‐ejection	
products	of	GL019	are	different	from	018	(see	Table	3.2),	ejecting	only	the	2‐Me‐8‐
HQ	ligand,	and	providing	a	narrow	phototherapeutic	window	of	2.	This	complex	is	
twice	as	slow	as	GL018	at	producing	the	active	Ru(dmphen)2	species	(see	Table	3.1)	
but	maintains	potency	with	a	light	activated	IC50	of	0.6	μM.	Both	of	these	complexes	
display	similar	affinity	to	pUC19	DNA	with	IC50’s	of	30	μM	observed	in	the	 in	vitro	
experiments	 (Table	 4.1).	 Derivatives	 containing	 both	 of	 these	 ligands	 should	 be	
synthesized	with	negatively	charged	backbones	such	as	Ru(bpds)2	(see	Table	2.1)	to	
attempt	 to	 reduce	 the	 dark	 toxicity	 issues	 associated	 with	 these	 complexes.	 The	
complex	GL022	ejects	 in	a	timely	manner	(5.4	minutes,	see	Table	3.1)	and	ejects	a	
mixture	of	products	(see	Table	3.2).		With	this	combination	of	ligands,	dark	toxicity	
is	 diminished,	 resulting	 in	 a	 phototherapeutic	 ratio	 of	 20.4.	 Complex	 GL023	 is	
slightly	slower	to	eject	at	15.2	minutes	(see	Table	3.1)	and	has	a	phototherapeutic	
window	of	2.5.	The	addition	of	the	bp	ligand	(see	Table	2.1)	is	thought	to	contribute	
to	the	dark	toxicity	through	increased	DNA	affinity	as	seen	smearing	of	the	DNA	in	
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the	 in	 vitro	 gels	 (see	 Figure	 4.6).	 A	 control	 complex	 of	 Ru(bpy)2bp	 should	 be	
synthesized	 to	 observe	 the	 dark	 toxicity	 associated	 with	 the	 ligand.	 GL039	 has	 a	
wide	 phototherapeutic	 window	 of	 61.8	 and	 is	 quick	 to	 eject	 at	 3.2	 minutes	 (see	
Table	 3.1)	 producing	 one	 active	 species	 (Ru(dmphen)dpq,	 see	 Table	 3.2).	 This	
complex	 contains	 a	 planar,	 intercalating	 ligand	 that	 has	 a	 high	 affinity	 to	 DNA	 as	
seen	in	the	in	vitro	pUC19	results	at	three	hours	(IC50	=	15	μM,	see	Table	4.1).	A	light	
activated	 in	 vivo	 IC50	 value	 of	 0.8	 μM	 is	 attributed	 to	 the	 ejection	 of	 the	 single	
dmphen	 ligand.	 The	 complex	 Ru(dpq)2dmphen	 should	 be	 synthesized	 to	 observe	
how	the	intercalating	dpq	ligand	starting	material	coupled	with	the	dmphen	ligand	
interact	with	DNA	and	cells.		
	
2)	Complexes	that	produce	single	strand	DNA	breaks	
	 Several	 research	 groups	 are	 synthesizing	 complexes	 that	 produce	 single	
strand	 breaks	 through	 the	 generation	 of	 reactive	 oxygen	 species	 (ROS).	 These	
complexes	are	described	in	the	literature.5	Three	complexes	highlighted	in	this	work,	
GL004,	005,	and	021,	also	produce	in	vitro	single	strand	DNA	breaks	(see	Figure	4.5).		
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Table	5.3:	Complexes	that	produce	in	vitro	single	strand	DNA	breaks	
Complex	
Code	
Name	
A549	Light	
(μM)	
A549	Dark	
(μM)	
A549	
phototherapeutic	
ratio	
GL004	 Ru(bpy)2phen	 40	 250	 6.3	
GL005	 Ru(bpds)2dmbpy	 1.3	 200	 154	
GL021	 Ru(bpy)2dpq	 123	 123	 1	
	
Figure	 5.4:	 Cytoxicity	 curves	 of	 example	 complexes	 that	 produce	 in	 vitro	 single	
strand	breaks	
	 	
	 Of	 these	 complexes,	 GL004	 is	most	 efficient	 at	 producing	 the	 in	vitro	 DNA	
breaks	 followed	 by	 GL021,	 and	 lastly	 GL005	 (15,	 30,	 and	 60	 μM	 respectively,	 see	
Table	 4.1).	 However,	 there	 is	 a	 disconnect	 in	 this	 design	 approach	 based	 on	 the	
efficiency	 to	 produce	 in	vitro	single	 strand	 breaks	 and	 A549	 cell	 cytotoxicity.	 The	
worst	 single	 strand	 breaker,	 GL005,	 is	 shown	 in	 Table	 5.3	 to	 produce	 the	 best	
phototherapeutic	window	of	154	(see	cytotoxicity	curve	in	Figure	5.5),	followed	by	
GL004	 (6.3)	 and	GL021	 (1).	 	 GL005	 is	 the	 only	 photoactive	 complex	 in	 the	 group	
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with	 a	 t1/2	 of	 0.6	 minutes	 (see	 Table	 3.1).	 This	 complex	 contains	 the	 Ru(bpds)2	
backbone	 and	 carries	 an	 overall	 charge	 of	 ‐2	 (see	 Table	 2.2),	 ejecting	 the	 dmbpy	
ligand	 upon	 light	 activation	 (see	 Table	 3.2).	 GL004	 contains	 the	 phen	 ligand	 (see	
Table	 2.1).	 This	 ligand	 is	 known	 to	 produce	 ROS,	 and	 a	 similar	 metal	 complex,	
Cu(phen)2,	 is	used	as	a	standard	to	produce	single	strand	breaks	in	the	 in	vitro	gel	
experiments	 (see	 Chapter	 4	 Experimental).2	 GL021	 has	 no	 distinguishable	
phototherapeutic	window	and	contains	an	intercalating	dpq	ligand	(see	Table	2.1).	
The	planar	nature	of	the	dpq	ligand	enhances	DNA	affinity	leading	to	dark	toxicity.5	
This	 complex	 intercalates	 as	 evident	 in	 the	 smearing	 of	 the	 DNA	 in	 the	 gel	 and	
shows	a	 fairly	efficient	 in	vitro	 IC50	of	30	μM	(see	Table	4.1)	 for	single	strand	DNA	
breaks.		Based	on	this	study,	designing	complexes	based	on	their	ability	to	produce	
single	 strand	 breaks	 does	 not	 correlate	 to	 in	vivo	cell	 cytotoxicity,	 at	 least	 in	 the	
A549	 cell	 line.	 Additional	 cell	 lines	 should	 be	 screened	 with	 these	 complexes	 to	
confirm	this	analysis.		
3)	Complexes	with	different	overall	charges	
	 The	majority	of	the	ruthenium	complexes	synthesized	for	this	work	have	the	
overall	oxidation	state	of	+2.	Complexes	with	overall	neutral	or	negative	charges	are	
of	interest	due	to	their	low	electrostatic	attraction	with	the	negatively	charged	DNA	
backbone.	 Decreased	 DNA	 affinity	 should	 decrease	 dark	 toxicity	 prior	 to	 light	
activation.	Negatively	charged	and	zero	charged	complexes	such	as	GL005	and	008	
display	this	property	with	decreased	dark	toxicity	IC50	values	seen	below.	
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Table	5.4:	Complexes	with	different	overall	charges	to	reduce	DNA	affinity	
Complex	
Code	
Name	
A549	Light	
(μM)	
A549	Dark	
(μM)	
A549	
phototherapeutic	
ratio	
GL005	 Ru(bpds)2dmphen	 1.3	 250	 154	
GL008	 Ru(bpy)2bcds		 56.3	 64.5	 1.2	
	
Figure	 5.5:	 Cytoxicity	 curves	 of	 complexes	 that	 contain	 different	 overall	 charge	
states.	
	 The	decreased	dark	toxicity	of	GL005	(overall	charge	of	‐2)	could	stem	from	
the	decreased	ionic	affinity	to	the	DNA.	This	complex	is	potent	when	light	activated	
(1.3	μM)	and	has	minimal	dark	toxicity	providing	a	phototherapeutic	window	of	154.	
A	full	series	of	complexes	containing	this	backbone	with	the	dmphen,	bp,	and	bcds	
ligands	(see	Table	2.1)	should	be	synthesized	and	screened	on	the	A549	cell	line	to	
grasp	 an	 understanding	 of	 how	 the	 overall	 negative	 charge	 affects	 in	vivo	 results.	
Complex	GL008	has	a	net	0	charge,		a	t1/2	of	12.6	minutes	(see	Table	3.1),	and	ejects	
the	bcds	ligand	upon	light	activation	(see	Table	3.2),	producing	the	Ru(bpy)2	active	
species.	 	 The	 negatively	 charged	 bcds	 ligand	 ejected	 appears	 to	 inhibit	 in	 vivo	
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toxicity	seen	in	the	model	complex	GL002	and	other	complexes	producing	the	same	
active	species	(see	5.1a).	To	see	how	net	0	charged	complexes	affect	pUC19	DNA	and	
the	A549	cell	line,	derivatives	such	as	Ru(dmphen)2bpds	should	be	synthesized.		
4)	Summary	and	future	work	
The	 flexible	coordination	chemistry	(see	Chapter	2.1)	of	ruthenium	offers	a	
unique	 approach	 for	 photodynamic	 therapy	 in	 that	 DNA	 affinity	 can	 possibly	 be	
reduced	 or	 gained	 based	 on	 electrostatics	 as	 well	 as	 structural	 features	 of	 the	
complex.	 To	 obtain	 DNA	 affinity,	 modifications	 to	 the	 structure	 should	 include	
intercalating	 ligands.	 Increased	 dark	 toxicity	 can	 also	 be	 obtained	 through	 the	
addition	 of	 bathophen	 or	 quinoline	 ligands	 and	 decreased	 dark	 toxicity	 can	 be	
achieved	 through	 addition	 of	 negatively	 charged	 ligands.	 These	 functionalities	
should	be	examined	in	future	works.	Complexes	displaying	a	red	shifted	absorption	
profile	 could	 improve	 the	 current	 PDT	 capabilities	 by	 penetrating	 deeper	 lying	
tumors.20	Derivatives	of	complexes	containing	ligands	that	display	cytotoxic	activity	
should	be	 coupled	with	 essentially	 inert	backbones.	The	 rich	nature	of	 ruthenium	
polypyridyl	 chemistry	 is	 well	 known.21	 As	 such,	 libraries	 of	 complexes	 can	 be	
synthesized	and	tested	for	cell	cytoxicity.	Combinatorial	approaches	are	known	and	
can	be	used	to	produce	and	screen	large	 libraries	of	complexes.6	A	comprehensive	
table	of	IC50	results	can	be	found	in	Table	5.5.	
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Table	5.5:	In	vivo	IC50	Values	
Complex	
Code	
Name	 A549
light	
(μM)	
A549	
dark	
(μM)	
A549	
ratio	
GL001	 Cisplatin	 1.5	 1.5	 1	
GL002	 Ru(bpy)2dmbpy	 0.6	 250	 417	
GL003	 Ru(bpy)2dmdpq	 1.2	 250	 216	
GL004	 Ru(bpy)2phen	 40	 250	 6.3	
GL005	 Ru(bathophendisulfonate)2dmbpy	 1.3	 250	 192	
GL006	 Ru(bpy)2‐3,3’dmbpy	 30	 250	 8	
GL007	 Ru(bpy)2dmphen	 0.1	 8	 80	
GL008	 Ru(bpy)2bathocuprionedisulfonate	 56.3	 64.5	 1.2	
GL009	 Ru(bpy)2dppz	 22	 22	 1	
GL010	 Ru(bpy)2dmdppz	 22	 47	 2.1	
GL011	 Ru(phen)2biquinoline	 4.2	 22.5	 5.4	
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Table	5.5:	In	vivo	IC50	Values	(cont.)	
Complex	
Code	
Name	 a549	
light	
(μM)	
a549	
dark	
(μM)	
a549	
ratio	
GL013	 Ru(bpy)22,2’biq‐3,3’dca	 >300	 >300	 1	
GL014	 Ru(bpy)2bathocuprione	 2.4	 9.3	 3.9	
GL018	 Ru(dmphen)28HQ	 0.3	 0.3	 1	
GL019	 Ru(dmphen)2‐2Me8HQ	 0.6	 1.2	 2	
GL021	 Ru(bpy)2dpq	 123	 123	 1	
GL022	 Ru(dmphen)2bpy	 1.2	 24.5	 20.4	
GL023	 Ru(dmphen)2bathophen 0.2	 0.5	 2.5	
GL039	 Ru(dmphen)2dpq	 0.8	 49.4	 61.8	
	
Chapter	5.2:	In	Vivo	A549‐GSH	Cell	Viability	Assay	
The	A549	 lung	 cancer	 cell	 line	 chosen	 for	 this	work	 is	 known	 for	 elevated	
glutathione	(GSH)	levels.	A	seven‐fold	increase	was	found	in	the	A549	cell	line	when	
compared	 to	 normal	 human	 lung	 fibroblast	 cell	 line	 (CCL‐210).14	 Normal	 cellular	
levels	of	GSH	range	from	1‐30	mM13c	The	many	roles	GSH	plays	in	cellular	activity	
are	discussed	in	Chapter	4.4.	Detoxification	of	antineoplastic	agents	such	as	cisplatin	
is	 performed	 by	 glutathione	 S‐transferases	 that	 bind	 the	 metal	 and	 are	 removed	
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from	 the	 cell	 via	 the	 ATP	 dependent	 GS‐X	 pump.22	 Elevated	 levels	 of	 GSH	 hinder	
cytoxicity	 of	 various	 antineoplastic	 drugs	 like	 melphalan,	 nitrogen	 mustard,	 and	
cisplatin.14,23	 In	 addition	 to	 decreased	 cytotoxicity	 from	 these	 common	
chemotherapeutics,	 radiation	 therapy	 is	 also	 compromised	 as	 a	 result	 of	 elevated	
GSH	levels.24		
To	ensure	the	synthesized	ruthenium	complexes	are	not	deactivated	by	GSH	
and	to	compare	the	in	vivo	effect	of	GSH	on	cisplatin	and	GL002,	a	dose	response	of	
GSH	 was	 performed	 where	 the	 amount	 of	 GSH	 was	 increased	 from	 0‐16	 mM	
followed	 by	 the	 addition	 of	 the	 cytotoxic	 complexes.	 Cisplatin	 and	 GL002	
concentrations	were	held	constant	at	20	μM.	The	IC50	of	cisplatin	in	the	absence	of	
GSH	was	 found	 to	 be	 1.5	 μM	 on	 A549	 cells	 (see	 Table	 5.5).	 	 Cisplatin	 results	 are	
shown	 in	 Figure	 5.6a	 and	 are	 consistent	 with	 the	 literature	 in	 that	 cell	 viability	
increases	with	 increasing	amounts	of	GSH.	Thus,	 cisplatin	becomes	a	 less	efficient	
cytotoxic	complex,	with	a	GSH	IC50	value	of	4.3	μM.	~100%	of	cells	are	viable	at	the	
top	GSH	concentration	of	16	mM.	
GL002	 was	 found	 to	 react	 minimally	 with	 GSH	 in	 dark	 experiments	 and	
slowly	 with	 GSH	 upon	 photo‐activation	 in	vitro,	 with	 a	 t1/2	=	 247.6	 minutes	 (see	
Figure	4.9b).	The	A549	IC50	value	for	the	activated	complex	GL002	is	0.6	μM	(Table	
5.5).	 Figure	 5.6b	 shows	 the	 GSH	 titration	with	 photoactivated	GL002.	 Glutathione	
seems	 to	 enhance	 cytotoxicity	with	 light	 activated	GL002.	No	 effect	was	observed	
with	 unactivated	 GL002.	 This	 combination	 of	 in	vitro	 and	 in	vivo	 studies	 indicate	
that	the	complexes	will	not	be	deactivated	by	GSH	both	prior	to	and	following	light	
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activation.	In	contrast,	addition	of	GSH	was	found	to	decrease	the	binding	efficiency	
and	cytotoxicity	of	cisplatin.	The	ability	of	the	synthesized	ruthenium	complexes	to	
evade	 detoxification	 by	 GSH	 while	 unactivated	 renders	 light	 activation	 of	 the	
complexes	 a	 viable	 PDT	 method.	 Similar	 in	 vitro	 pUC19	 gel	 experiments	 were	
carried	out	by	contributing	scientists	 in	our	 lab	with	similar	results.	Future	 in	vivo	
A549	light	activated	studies	should	be	performed	to	determine	the	amount	of	GSH	
required	 for	 the	 complete	 deactivation	 of	 photo‐activated	 GL002.	 	 These	 results	
indicate	 that	 the	ruthenium	PDT	strategy	does	not	suffer	 the	same	 inactivation	by	
biological	 thiols	as	platinum	agents	at	physiological	 concentrations	of	GSH.	Future	
studies	 should	 focus	 on	 the	 ability	 of	 ruthenium	 agents	 to	 avoid	 alternative	
detoxification	mechanisms	associated	with	cisplatin	resistance.	
Figure	5.6:	GSH	Titration	with	a)	CP	and	b)	GL002	
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Chapter	5	Experimental	
A549	Growth	Inhibition	Assays	Experimental	
A549	cell	viability	assay	
A549	cells	were	obtained	 from	Dr.	Rolf	Craven	and	were	grown	in	Dubelco	
Minimum	 Essential	 Medium	 (DMEM),	 with	 Earle’s	 Balanced	 salt	 solution	 (ATCC)	
supplemented	 with	 10%	 (v/v)	 Serum	 Supreme	 (Lonza,	 Biowhittaker)	 and	 1%	
Penicillin/	 Streptomycin	 (Gibco).	 	 Cells	were	maintained	 at	 37	 oC	 in	 a	 humidified	
atmosphere	of	95%	air	and	5%	CO2.	
All	compounds	were	screened	for	cytoxicity	in	the	absence	of	light	and	after	
light	 activation.	 Light	 and	 dark	 toxicity	 screens	 were	 carried	 out	 on	 cell	 passage	
numbers	between	7	and	15	in	96	well	plates	(Costar)	in	Optimem	I	Reduced	Serum	
Medium	 with	 1%	 Serum	 Supreme	 and	 1%	 Penicillin/	 Streptomycin	 (Gibco)	 in	
duplicate.	 	The	cells	were	seeded	in	the	96	well	plates	(50	μL)	at	a	density	of	1.5	x	
103	 cells	 per	 well	 and	were	 allowed	 to	 adhere	 for	 at	 least	 four	 hours	 before	 the	
addition	of	compound.	
600	 μM	 stock	 solutions	 of	 the	 ruthenium	 complexes	 were	 prepared	 in	
Optimem	with	1%	Serum	Supreme	on	a	separate	96	well	plate.		220	μL	were	added	
to	 all	 other	wells	 and	 1:3	 serial	 dilutions	were	 performed	by	 transferring	 110	 μL	
down	 each	 column	 of	 the	 96	 well	 plate	 to	 give	 the	 following	 compound	
concentrations:	600	μM,	200	μM,	67	μM,	22	μM,	7.4	μM,	2.4	μM,	0.8	μM,	0	μM.		Once	
these	dilutions	were	prepared,	50	μL	of	the	metal	solutions	were	transferred	to	the	
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96	 well	 plate	 containing	 50	 μL	 of	 cells	 (1:2	 dilution)	 to	 give	 the	 final	 ruthenium	
concentrations:	300	μM,	100	μM,	33.5	μM,	11	μM,	3.7	μM,	1.2	μM,	0.4	μM,	and	0	μM.	
During	the	addition	of	the	ruthenium	complexes	to	the	cells,	care	was	taken	
to	protected	 the	 compounds	 from	 light.	After	 compound	addition,	 the	plates	were	
covered	with	aluminum	foil	to	continue	their	protection	from	light	and	incubated	at	
37	 oC	 with	 5%	 CO2	 in	 a	 humidified	 atmosphere	 for	 96	 hours.	 Cell	 viability	 was	
subsequently	measured	with	the	Cell	Titer‐Glo	Luminescent	Cell	Viability	Assay	Kit	
(Promega).	 Viability	 was	 measured	 using	 a	 Tecan	 Spectrafluor	 Plus	 plate	 reader	
equipped	 with	 Magellan	 v7.0	 software.	 The	 luminescent	 signal,	 due	 to	 the	
conversion	of	luciferin	and	ATP	to	oxyluciferin,	AMP,	and	light,	was	measured	after	a	
five	minute	incubation	of	the	cells	with	the	cell‐titer	glo.	During	this	time	complete	
cellular	 lysis	 occurred	 allowing	 for	 maximal	 signal	 with	 minimal	 well	 to	 well	
variability.	
Upon	 overnight	 incubation	 of	 the	 compounds	 in	 the	 absence	 of	 light,	 light	
activation	studies	were	carried	out	using	a	3M	overhead	projector	(model	955)	with	
an	 82	 V/	 410	 W	 lamp	 (Model	 Osram	 FXL)	 fitted	 with	 a	 blue	 light	 cutoff	 filter	
(Edmund	Optics,	part	#	NT43‐941)	and	a	mirror	angled	at	45	degrees	to	reflect	the	
light	downward	onto	 the	96	well	plates.	The	96	well	plates	were	exposed	 to	blue	
light	for	three	minutes	and	returned	to	the	incubator	for	72	hours.	Cell	viability	was	
measured	 with	 the	 aforementioned	 Promega	 Cell	 Titer‐Glo	 Luminescent	 Cell	
Viability	 Assay	 Kit.	 IC50	 values	 were	 calculated	 utilizing	 Prism	 software	 with	 the	
curves	fit	to	a	Variable	Slope,	Log(inhibitor)	vs.	Response	equation.	
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Chapter	5.2:	In	Vivo	A549‐GSH	Cell	Viability	Assay:	Experimental	
A549	cells	were	plated	in	a	similar	fashion	described	in	5.1	at	1500	cells/well.	
Identical	dark	assay	conditions	as	described	in	Ch.	5.1	Experimental	were	employed,	
but	 with	 	 the	 addition	 of	 L‐glutathione	 (GSH).	 	 Experiments	 were	 carried	 out	 in	
triplicate	using	Cisplatin	and	GL002	to	determine	the	effect	GSH	has	on	cell	viability.	
Cisplatin	and	GL002’s	concentrations	were	held	constant,	at	a	concentration	of	20	
μM,	and	GSH	was	subsequently	added	in	dose	response	at	concentrations	of	16	μM,	
8	μM,	4	μM,	2	μM,	1	μM,	0.5	μM,	0.25	μM,	and	0.125	μM.	GL002	was	light‐activated	
after	a	12	hour	incubation,	and	viability	determined	after	a	total	incubation	time	of	
96	hours.		The	effect	of	GSH	with	cisplatin	was	measured	after	a	96	hour	incubation	
with	 the	 cells.	 	 Viability	 was	 measured	 with	 the	 ATP	 Luciferase	 assay	 and	 the	
aforementioned	Tecan	plate	reader	at	96	hours.	IC50	values	were	calculated	utilizing	
Prism	software	with	the	curves	 fit	 to	a	Variable	Slope,	Log(inhibitor)	vs.	Response	
equation.	
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